

Index

A

- A33, 472
 AAL. *See* *Aleuria aurantia* lectin
 AAVS1, 758
 ABO, 168–169
 ABO blood group antigens
 antibodies, 171
 cancer alterations, 626, 637
 clinical considerations, 171
 discovery, 168, 645
 genetics, 169–170
 polymorphisms, 274
 synthesis, 134, 168–170, 169f, 170f
 tissue distribution of determinants, 170
 transfusion reaction, 620, 781
 Abrin, 658
Acanthamoeba keratitis, 580
Acanthocheilonema viteae, 346
 Acarbose, 773f, 775t
 ACE. *See* Affinity co-electrophoresis
 ACE2, 507, 563, 623
 Acetyl-CoA, 45
 ACG-IB. *See* Achondrogenesis type IB
 Achondrogenesis type IB (ACG-IB), 609
 Acid glucosylceramidase (GBA), 730
 Acinetaminic acid, 201
 ACP2, 445, 452
 ACP5, 445
 Acrosome reaction, 210
Actinobacillus pleuropneumoniae, 246, 291
 Actinohivin (AH), 428
 Acute respiratory distress syndrome, 627
 Acquired human diseases, 615–628.
 See also specific diseases
 Acquired immunodeficiency syndrome
 (AIDS), 565
 AD. *See* Alzheimer's disease
 ADAM3, 152
 ADAM10, 152, 159
 ADAM17, 159, 470
 Adams–Oliver syndrome (AOS), 160
 ADAMTS, 161
 ADAMTS9, 535
 ADAMTS13, 535
 ADAMTSL1, 535
 ADAMTSL2, 535
 ADCC. *See* Antibody-dependent cell-mediated cytotoxicity
 Adenovirus, 507
 Adipogenesis, galectin role, 500
 AdoMet. *See* S-adenosyl methionine
 ADPK. *See* Autosomal-dominant polycystic kidney disease
 Advanced glycation end products (AGEs), 617
 Aerolysin, 425, 428
Aeromonas hydrophilia, 153
 Affinity chromatography, glycan-binding protein studies, 391–392, 392f, 654, 655f, 656
 Affinity co-electrophoresis (ACE), glycan-binding protein studies, 399
 AFM. *See* Atomic force microscopy
 AFP-L3, 642
 African sleeping sickness, 152
 AG. *See* Arabinogalactan
 A3GALNT, 169
 A3GALT1, 169
 A4GALT, 173–174, 621
 AGEs. *See* Advanced glycation end products
 Agglutination, glycan-binding protein studies, 398–399
 Agglutinin, 421, 433, 435
 Aggrecan, 209–210, 210f, 219, 221, 224, 471
Aggregatibacter aphrophilus, 246
 Aggrus. *See* Podoplanin
 Agl3, 305
 AglA, 304
 AglB, 303–305
 AglC, 304
 AglD, 303
 AglE, 303
 AglF, 303
 AglG, 303
 AglH, 305
 AglI, 303
 AglJ, 303
 AglK, 304
 AglM, 303
 AglP, 303
 AglQ, 303
 AglR, 303
 AglS, 303
 AglT, 305
 Aglycone, glycoconjugate, 5
 Agrin, 221, 223
Agrobacterium tumefaciens, 292
 AgtA, 240
 AH. *See* Actinohivin
 AIDS. *See* Acquired immunodeficiency syndrome
 AKT, 213, 638
 Alditol, formation, 28
 Aldolase B. *See* Fructoaldolase
 Aldose, definition, 3
Aleuria aurantia lectin (AAL), 654
 ALG1, 602f
 Alg5, 351
 Alg7, 304
 ALG7, 106
 Algae
 glycans, 331
 glycosyltransferases, 332
 Viridiplantae clades, 319
 ALG1-CDG, 602t, 604
 ALG6-CDG, 618
 Alginate, 332, 724f
 α 1-antitrypsin, 437
 α -DG. *See* α -dystroglycan
 α -dystroglycan (α -DG), 155, 161–162, 183, 271, 606, 665
 α 1-2 fucosyltransferase, 121f, 125, 339–340, 341, 566, 659.
 See FUT1, FUT2
 α 1-3 fucosyltransferase, 469, 470, 566, 659, 732, 762. *See* FUT3, FUT4, FUT5, FUT6, FUT7, FUT9
 α 1-6 fucosyltransferase (FUT8), 111, 340, 342, 350, 632, 672
 α -galactosidase, 593
 α 1-3 galactosyltransferase, 69, 76, 94
 α 4-galactosyltransferase, 138
 α -glucosidase I (MOGS), 108, 530, 597
 α -glucosidase II (GANAB), 108, 530–531
 α -iduronidase, 587t, 590–591, 596–597
 α -L-iduronidase deficiency, 596
 α -linkage, 5, 7
 α -mannosidase, 533–534, 588
 α -mannosidase I (MAN1B1), 110, 533–534, 603f, 605
 α -mannosidase IA (MAN1A1), 110
 α -mannosidase IB (MAN1A2), 110
 α -mannosidase IC (MAN1C1), 110
 α -mannosidase II, 110, 330
 α -mannosidosis, 586t
 α 1-3 N-acetylgalactosaminyltransferase, 134, 427f
 α -N-acetylglucosaminidase, 590
 α 2-3 sialylated glycan, 178–179
 α 2-3 sialyltransferases, 68
 α 2-6 sialylated glycan, 179–180, 180f
 α 2-8 sialylated glycan, 180–182, 181f
 ALS. *See* Amyotrophic lateral sclerosis
 Alzheimer's disease (AD), 260–261, 617, 625–626
 AMAN-1, 340
 AMAN-2, 340

- AMAN-3, 340
 Amaranthin, 424–425
Amaranthus caudatus, 424
 Amber, 413
Ambyostoma mexicanum, 494
 Amebiasis. *See Entamoeba histolytica*
 4-amino-DANA, 749f
 Aminoglycoside antibiotics, 17
 AMPK, 247, 256
 AMR. *See* Ashwell–Morell receptor
 Amyloid- β , 485
 Amyotrophic lateral sclerosis (ALS), 261
Anaplasma phagocytophilum, 468
Ancylostoma duodenale, 571t
 ANGPTL3, 608
 Annexin V, 383
 Anomeric center
 configuration determination, 27f
 glycosidic bond formation, 29f
 mutarotation, 27
 oxidation, 27–28, 28f
 reduction, 27–28
 Schiff base formation, 28
 Antibody. *See* Monoclonal
 antibodies to glycan antigens;
 specific immunoglobulins
 Antibody-dependent cell-mediated
 cytotoxicity (ADCC), 551, 694
 Antithrombin, 377, 522–523, 523f
 Antithrombin III, 551, 619
 ANTS, 680
 AOS. *See* Adams–Oliver syndrome
 AP1, 449
 AP2, 449
 AP-3, 261
 AP-180, 261
 APAP1, 323f, 330
 APOCIII, 608
 Apoptosis
 cancer suppression, 214
 galectin role, 247, 499
 Siglec triggering, 487
Arabidopsis, 98, 151, 258, 541–542, 658–659
Arabidopsis thaliana
 galectins, 493
 glycoengineering, 762
 mutants, 323
 Arabinofuran, 286
 Arabinogalactan (AG), 280, 286, 779
 Arabinogalactan proteins, 330
 Arabinoglucuronoxylan, 328
 Arabinoxylan, 321f, 326
Arachis hypogaea, 98
 Archaea
 cell wall
 diversity, 299
 polysaccharides, 298, 300–301, 302f
 glycome, 98
 glycosylation
 diversity, 273, 301–302
 functions, 305
 halophilic euryarchaeota, 303
 methanogenic euryarchaeota, 304
 O-glycans, 305
 overview, 46
 pathways, 301, 303
 thermophilic crenarchaeota, 304–305
 history of study, 297–298
 N-glycans, 302f
 O-glycans, 302f
 R-type lectin, 428–429
 Arixtra, 778
 Arteriovenous malformation, 627
Arthrobacter ureafaciens, 193
 Arthropods. *See* Insects
 Arylsulfatase A, 593
 Arylsulfatase B, 597
Ascaris lumbricoides, 571t
Ascaris suum, 346
 ASGPR. *See* Asialoglycoprotein receptor
 Ashwell, Gilbert, 376
 Ashwell–Morell receptor (AMR), 455–456,
 458–460, 550, 553, 622
 Asialoceruloplasmin, 376
 Asialoglycoprotein receptor (ASGPR), 178,
 376–378, 399, 449, 455
 Aspartylglucosaminuria, 586t
Aspergillus fumigatus, 142–143
Aspergillus niger, 142
 Asthma, 626–627
 Atelosteogenesis type II, 609
 Atherosclerosis, glycan roles, 616
 Atomic force microscopy (AFM), glycan-
 binding protein studies, 396
 AuNP. *See* Gold nanoparticle
 Australine, 743f
 AutoDock, 413
 AutoDock Vina, 413
 Autoimmune disease. *See* *specific diseases*
 Automated glycan assembly. *See* Chemical
 synthesis, glycans
 Autosomal-dominant polycystic kidney
 disease (ADPK), 471
 Avery, Oswald, 556
- B**
- BabA, 566
Bacillus anthracis, 556
Bacillus sphaericus, 428
Bacillus thuringiensis (Bt), 342, 344, 513
 Bacteria. *See also* Gut microbiota; *specific*
 bacteria
 adhesin–glycan interactions, 511t
 cell envelope
 architecture overview, 280, 281f
 Gram-positive bacteria cell walls, 284,
 285f, 286
 mycobacteria, 286
 peptidoglycan
 cell wall assembly, 283–284
 structure, arrangement, and
 function, 280, 282–283, 282f
 synthesis therapeutic targeting, 284
 colonization and invasion
 adhesins and receptors, 560–561
 biofilm, 561–562
 invasion factors, 561
 extracellular polysaccharides
 assembly and export, 294–295
 structure and function, 292–294
 glycoengineering
 N-glycans, 760–761
 O-glycans, 761
 oligosaccharide engineering, 760
 overview, 759
 glycome, 97
 glycosylation
 diversity, 273
 overview, 46, 60–61
 hyaluronan capsules, 213
 lectins, 509–513
 lipopolysaccharide
 assembly and export, 289–290
 function, 288–289
 structure, 286–288
 osmoregulated periplasmic glucans,
 291–292
 polysaccharide detection, 679
 polysaccharide features, 39–42
 prospects for glycobiology studies, 295
 protein glycosylation, 290–291
 R-type lectin, 428
 toxin receptors, 512t
 virulence factors
 lipopolysaccharide, 558–560
 polysaccharide capsules, 556–558
Bacteroides fragilis, 85
Bacteroides thetaiotaomicron, 566
 Baculovirus, 97
 BAD. *See* BCL-2 antagonist of cell death
 Basigin (CD147), 477
 B-cell receptor (BCR), 180, 481–482, 488
 Bcl-2, 499
 BCL-2 antagonist of cell death (BAD), 213
 BCR. *See* B-cell receptor
 BDCA-2, 462
 BDNF, 181, 190
 BEL, 425
 β -1,3-acetylglucosaminetransferase, 732
 β -cyclodextrin, 792
 β -1-3 galactosyltransferase, 176
 β -1-4 galactosyltransferase, 68, 76f, 175–176,
 732
 β -galactosidase, 593, 678t
 β -glucocerebrosidase, 136, 452, 592–593
 β -glucosyltransferase, 73
 β -glucuronidase, 588, 591
 Betaglycan, 222
 β -hexosaminidase, 138, 762
 β -human chorionic gonadotrophin, 71f, 83
 β -linkage, 5, 7
 β -mannosidase, 588
 β -mannosidosis, 586t
 β -1-2 N-acetylglucosaminyltransferase, 73
 β -1-3 N-acetylglucosaminyltransferase, 158
 β -N-acetylhexosaminidase, 591–592, 596
 β -N-hexosaminidase, 588
 β -trefoil fold, 423, 424f
 B3GALNT1, 173–174, 621
 B3GALNT2, 162, 607
 B4GALNT1, 138, 178, 483, 610
 B4GALNT2, 178

- B4GALNT3, 176
 B4GALNT4, 176
 B3GALT5, 124
 B3GALT6, 608
B4GALT1, 550, 762
 B4GALT2, 605
 B4GALT7, 224, 608
 B4GALT1-CDG, 605
 B3GAT1, 182
 B3GAT2, 182
 B3GAT3, 608
 B4GAT1, 162, 607
B3GLCT, 160–161
 Biglycan, 221
 B3GNT3, 124
 B3GNT6, 124
 Bioenergy, 798–799, 807
 Biofilm, 294, 561–562, 562f
 Biolayer interferometry (BLI),
 glycan-binding protein studies, 395
 BiP, 531, 536
 Bi-specific T-cell engager (BiTE), 126
 BiTE. *See* Bi-specific T-cell engager
 BLI. *See* Biolayer interferometry
 BNButGT, 745
 Botulinum toxin, 138, 428
 Bovine serum albumin (BSA), 647–648
Bradyrhizobium, 292
 Breast cancer, 642
 Brefeldin A, 740f, 741
 Brevican, 209, 221, 471
brn, 362–363
Brugia malayi, 571t
 BSA. *See* Bovine serum albumin
 Bt. *See* *Bacillus thuringiensis*
 Burkitt's lymphoma, 637
 BX7B motif, 212
 Byonic, 712t
- C**
- CA19-9, 626, 642
 CA125, 642
 CAD. *See* Cold agglutinin disease
Caenorhabditis elegans, 99, 113, 163, 206,
 258, 260, 269, 271
 body parts, 336f
 chondroitin
 proteoglycans, 343f
 synthesis, 339f
 C-type lectins, 457
 developmental biology, 335–336
 galectins, 493
 glycan overview, 337–339
 glycan-binding proteins, 344–345
 glycobiology in other nematodes,
 345–346
 glycolipids, 344–345, 345f
 glycosphingolipids, 337
 glycosyltransferases, 339–341
 life cycle, 336f
 N-glycans, 337, 338f, 340–341, 346f
 O-glycans, 337, 338f, 341–342
 proteoglycans, 342–344
- Callose, 320, 321f, 327
 Calnexin, 96, 363, 378, 436–437, 438f,
 530–533, 536–537
 Calreticulin, 96, 363, 378, 436–437, 438f,
 530–533, 536–537
 Cambridge Structural Database, 688
 CAMKII, 256
 CAMKIV, 256
Campylobacter jejuni, 138, 273, 291, 425,
 481, 558–559, 625, 759–760
Canavalia ensiformis, 646
 Cancer. *See also specific cancers*
 galectin studies, 499
 glycosylation changes
 blood group expression, 637
 cancer stem cells during epithelial-to-
 mesenchymal transition, 641–642
 clinical significance, 642–643
 glycosaminoglycan changes, 638–640,
 639f
 glycosphingolipid expression, 637
 glycosylphosphatidylinositol anchor
 expression, 637–638
 history of study, 631–632
 hyaluronan expression, 638
 mechanisms, 641
 mucin expression, 633–634, 634f
 N-glycan branching and fucosylation,
 632–633
 nonrandom changes, 632
 O-GlcNAc glycan studies, 262, 640–642
 O-glycan truncation, 634, 634f
 overview, 626
 selectin ligand expression, 636–637,
 636f
 sialic acid
 expression, 199, 635–636
 O-acetylation, 619
 prospects for glycan studies, 811
 vaccines, 780–781
 The Cancer Genome Atlas (TCGA), 641
Candida albicans, 151, 427, 497–498
 Capillary electrophoresis, 680, 695
 Capsular polysaccharide (CPS), 39, 41, 280,
 292–295, 293f, 760
 CAR. *See* Chimeric antigen receptor
 Carbohydrate-Active Enzymes database
 (CAZy), 72, 94–95, 420, 758, 809
 Carbohydrate-binding module (CBM)
 CBM13, 420
 cell-surface glycoconjugate
 characterization, 656–657
 examples, 653f
 glycan identification, 652
 overview of glycan-recognizing probe use,
 646
 Carbohydrate-recognition domain (CRD),
 96, 375, 379–385, 380f, 384f,
 388–389, 419–420, 420f, 432,
 456, 491, 494–495, 506
 Carbon nanotube (CNT),
 glyconanomaterials, 790–791, 791f
 Cardin, Alan, 521
 CAR-T, 126
 CAR-T cell, 642–643
 CASD1, 77, 192
 CASPER, 712t, 714
 Castanospermine, 743f
Castanosperum australe, 743f
 Cataract, 214
 Cathepsin A, 588
 Cathepsin D, 446
Caulobacter crescentus, 246
 CAZy, 710t
 CAZy. *See* Carbohydrate-Active Enzymes
 database
 CBM. *See* Carbohydrate-binding module
 CBP35. *See* Galectin-3
 CBP70, 243
 CBT. *See* Consolidated bioprocessing
 technology
 CCARL, 97, 715
 CCL5 (RANTES), 524–525, 524f
 CCL19, 468
 CCL21, 468
 CCR5, 525, 565
 CCR7, 85
 CCSD. *See* Complex Carbohydrate
 Structure Database
 CD1a, 551
 CD1d, 137
 CD2, 478
 CD7, 499
 CD11b, 487
 CD14, 151, 558–559
 CD15, 550. *See* Lewis x
 CD15s. *See* Sialyl Lewis x
 CD22, 77, 90, 180, 275, 379, 476, 478–479,
 481–482, 482f
 CD24, 385, 488, 641
 CD29, 499
 CD33 (Siglec-3), 197, 476, 480, 485, 485f
 CD34, 470
 CD37, 211
 CD38, 211
 CD43, 499
 CD44 (HCELL), 208, 211, 213, 222–223,
 385, 466–467, 466f, 469, 471,
 545, 561, 617, 638, 641–642
 CD45, 427, 481, 499
 CD47, 488
 CD52, 152
 CD55, 153
 CD57, 182
 CD59, 152, 620
 CD62E. *See* E-selectin
 CD62L. *See* L-selectin
 CD62P. *See* P-selectin
 CD71, 499
 CD74, 222
 CD83, 478
 CD95, 499
 CD133, 641
 CD147. *See* Basigin
 CD162. *See* P-selectin glycoprotein ligand-1
 CD168. *See* RHAMM
 CD169. *See* Sialoadhesin
 CD206, 427

- CD209a (SIGN-R1), 462
 Cdc48, 534
 CD33-related Siglecs
 genomic organization, expression
 patterns and functions
 CD33, 484f, 485, 485f
 overview, 484
 Siglec-5, 486
 Siglec-6, 486
 Siglec-7, 486–487
 Siglec-8, 487
 Siglec-9, 486–487
 Siglec-10, 488
 Siglec-11, 488
 Siglec-14, 486
 Siglec-16, 488
 Siglec-E, 486–487
 Siglec-F, 487
 Siglec-G, 488
 nonsialylated ligands, 489
 CDG. *See* Congenital disorders of glycosylation
 CDG-Ib, 776
 CDG-IIc, 776
 CD-MPR. *See* Mannose-6-phosphate receptor
 CDP-ribitol, 162
 CEA, 642
 CEACAM5, 637
 CEBiP, 542
 CEL-III, 426
 Cell culture glycosylation mutants
 cell lines from mice and humans, 667
 Chinese hamster ovary cells, 663–664, 668, 670–672
 CRISPR/Cas9, 664, 666
 dominant mutants, 664f, 669, 669t
 embryonic stem cells, 667
 glycolipid synthesis mutants, 671
 GPI anchor biosynthesis mutants, 669–670
 HAP1 cells, 664, 666
 historical perspective, 663–664
 O-glycan synthesis mutants, 671
 proteoglycan assembly mutants, 670–671, 670t
 recessive mutants, 664f, 667–669, 668t
 research applications, 671–673
 selection and isolation of mutants, 665f, 666–667
 Cell wall. *See* Archaea; Bacteria; Fungi; Plants; *specific components*
 Cellulose, 272, 801f, 802f
 depolymerization, 326
 linkages, 5
 microfibrils, 325–326
 structure, 35–36, 36f, 320
 torsion angle, 36
 Cellulose nanocrystal (CN), 793, 799–800
 CEMIP. *See* KIAA1199
 Ceramide, 130, 132
 Cerezyme, 597
 CERK1, 542
 Ceruloplasmin, 458
 CFG. *See* Consortium for Functional Genomics
 CFTR, 627
 C1GALT1, 123, 125–126, 371, 608, 634
 C1GALT1C1 (COSMC), 123, 125, 605, 608, 621, 624, 634, 656, 699, 767
 CGL, 425
 CGNT1, 167
 CGNT3, 167
 CGNT4, 167
 Chagas disease, 569, 574, 580
 Chain terminator, glycosylation inhibitors, 748–749
 Chair conformation, monosaccharide structure, 25–26
 Chaperone therapy. *See* Pharmacological chaperone therapy
 CHARMM, 413
 Chemical synthesis, glycans
 automated glycan assembly examples, 722, 724f, 725–726, 725f
 computer-assisted glycan assembly, 726–727, 726f
 prospects, 727, 808–809
 protective group manipulations, 721–722, 721f
 Pseudomonas aeruginosa
 exopolysaccharide, 722, 723f
 regiochemistry control, 719–720
 stereochemistry control, 720–721
 Chemoenzymatic synthesis, glycans
 flavonoid glycosides, 734f
 glycosidase mechanism, 729–730
 glycosyltransferase
 chemoenzymatic synthesis of glycans, 730–732, 733f
 mechanism, 729–730
 glycosynthases, 732–735, 736f, 737
 prospects, 737, 808–809
 Chimeric antigen receptor (CAR), 634
 CHIME syndrome, 602t
 Chinese hamster ovary cell. *See* Cell culture glycosylation mutants; Glycoengineering
 Chitin, 272, 361
 polymer production, 799–800
 structure, 36
Chlamydia tracheomatis, 501
Chlamydomonas reinhardtii, 331
 Chloroplast, membrane protein glycosylation, 242
 C9-4HMT-DANA, 750
 Cholera toxin, 138, 511, 512f, 618
 Chondroitin
 nematodes, 337, 339f, 343
 structure, 11, 37
 Chondroitinase ABC, 678t
 Chondroitinase AC, 678t
 Chondroitinase B, 678t
 Chondroitin polymerizing factor (CHPF), 226
 Chondroitin sulfate (CS), 194
 cancer changes, 638, 640
 CCL5 interactions, 524–525, 524f
 composition, 220
 C-type lectin domains, 471
 degradation, 592f
 degradation defects, 591–592
 glyconutrient, 779
 hyaluronan complex, 210f
 history of study, 217
 insects, 359
 neurobiology, 554
 synthesis, 39, 225–227, 225f, 227f
 types, 228t
 Chondroitin sulfate A (CSA), 572
 CHPF. *See* Chondroitin polymerizing factor
 Chronic kidney disease (CKD), 624
 Chronic obstructive pulmonary disease (COPD), 486
 CHST1, 182, 225
 CHST2, 182
 CHST3, 225
 CHST4, 182, 225
 CHST6, 225
 CHST8, 176
 CHST9, 176
 CHST10, 182
 CID. *See* Collision-induced dissociation
 CI-MPR. *See* Mannose-6-phosphate receptor
 c-Jun, 486
 CKD. *See* Chronic kidney disease
 CL-43, 461
 CL-46, 461
 CLEC1, 462
 CLEC2, 462, 464
 CLEC4E. *See* MINCLE
 CLEC6A, 462
 CLEC9A (DNGR-1), 461–464
 CLEC10A, 465
 CLEC12A, 463
 CLEC12B, 462–463
 CLEC17A. *See* Prolectin
 CL-K1, 461
 CL-L1, 461
Clonarchis sinensis, 571t
Clostridiodes, 295
Clostridium botulinum, 428
Clostridium difficile, 237, 513, 780
Clostridium novii, 237
Clostridium perfringens, 623
Clostridium sordellii, 237
 CL-P1, 461
 CMAH, 190, 199, 270
 C-mannosylation, 163–164, 164f
 CMAS, 611
 CMD. *See* Congenital muscular dystrophy
 CMP-Kdo, 289
 CMP-NeuAc, 741, 746
 CMP-Neu5Ac, 77, 192, 200, 559, 762–763
 CMP-Neu5Ac hydroxylase, 371
 CMP-Neu4Gc, 191
 CMP-Neu5Gc, 93
 CMP-sialic acid, 731, 760, 764, 776
 c-Myc, 260, 641
 CN. *See* Cellulose nanocrystal
 CNL, 425

- CNT. *See* Carbon nanotube
 COG3, 612
 COG7, 602t
 COG7-CDG, 602t, 612
 COG complex. *See* Conserved oligomeric Golgi complex
 Cold agglutinin disease (CAD), 167, 174, 621
 COLGALT1, 163
 COLGALT2, 163
 Collagen, O-glycans, 163
 Collectin. *See* C-type lectin
 Collision-induced dissociation (CID), 697, 698f, 700, 713
 Colominic acid, 190
 Colorectal cancer, 199, 642
 Common Fund, 808
 Complex carbohydrate, definition, 22
 Complex Carbohydrate Structure Database (CCSD), 708
 ConA. *See* Concanavalin A
 Concanavalin A (ConA), 376, 431–432, 432f, 434, 436, 646, 652, 654, 655f, 658
 Congenital disorders of glycosylation (CDG) classification, 601
 dolichol synthesis defects, 612
 glycosaminoglycan synthesis defects, 608–609
 glycosphingolipid synthesis defects, 610
 glycosylphosphatidylinositol anchor synthesis defects, 609
 Golgi homeostasis defects, 612–613
 history of study, 599–600, 601f
 N-glycan biosynthesis defects clinical features and diagnosis, 600–601
 endoplasmic reticulum defects, 601, 604–605, 606f
 Golgi defects, 606f
 overview, 603f
 deglycosylation defects, 605
 O-glycan biosynthesis defects
 O-GalNAc synthesis defects, 607–608
 O-mannose synthesis defects, 606–607, 606f
 overview of defects, 600, 602t
 prospects for study, 613–614
 sugar synthesis defects
 fucose, 611–612
 galactose, 610–611, 611f
 sialic acid, 611
 Congenital muscular dystrophy (CMD), 161–162, 606–607
 Conglutinin, 461
 Conserved oligomeric Golgi (COG) complex, 49
 Consolidated bioprocessing technology (CBT), 798
 Consortium for Functional Genomics (CFG), 96–97, 708
 Contactin, 182
 COPD. *See* Chronic obstructive pulmonary disease
 COPI vesicle, 49, 533
 COPII vesicle, 49, 150, 531, 533
Coprinopsis cinerea, 493
 Core fucose, 346, 350, 588, 648, 652, 654, 694, 756–757t
 Cori, Gerty, 3f
 Cosmc, 464, 469–470, 621
 COSMC. *See* C1GALT1C1
 COSY, 687
 Cox2, 637
 CPG-1, 343
 CPG-2, 343
 CPS. *See* Capsular polysaccharide
 CRD. *See* Carbohydrate-recognition domain
 C-reactive protein (CRP), 439
 CREB, 260
 CRIPTO, 152
 CRISPR/Cas9, 370f, 664, 666, 699, 758, 763, 768
 Crizanlizumab, 468
Crotalus atrox, 472
 CRP. *See* C-reactive protein
 CRPPA. *See* D-ribitol-5-phosphate cytidyltransferase
 CRPPA, 607
 Cry5B, 344
 Cryo-electron microscopy
 CI-MPR, 448
 glycan-binding protein structure studies, 411–412, 412f
 prospects, 808
Cryptosporidium parvum, 258, 513, 570t, 580
 Crystallography. *See* X-ray crystallography
 CS. *See* Chondroitin sulfate
 CSA. *See* Chondroitin sulfate A
 CSP, 571t, 573
 c-Src, 545
 CstII, 415
 CT1, 178
 CT2, 178
 CT antigen. *See* Sda blood group antigen
 CTD domain, 259
 CTLD. *See* C-type lectin domain
 Cultured cells. *See* Cell culture glycosylation mutants
 C-type lectin
 Ashwell–Morell receptor, 458–460
 collectins, 459, 461–462
 endocytic receptors, 460f
 history of study, 455–456
 myeloid cell lectins, 462–465
 proteoglycans with C-type lectin domains, 471
 selectins, 465–471
 signaling in immune response, 463f
 structure, 456, 457f, 459f
 subfamilies, 456–457
 C-type lectin domain (CTLD), 455
 CTL fold, 456
 nematodes, 345
 CXCR4, 565
 Cyclin D1, 641
 Cystatin-C, 525
 Cystic fibrosis, 536, 627
D
 DAD1, 106
 DAG. *See* Diacylglycerol
 Dally, 359–360
 Damage-associated molecular patterns (DAMPs), 85, 488, 540, 546
 DAMPs. *See* Damage-associated molecular patterns
 DANA, 749–750, 749f
Danio rerio. *See* Zebrafish
 DAP12, 480, 483, 485
 Databases. *See* specific databases
 DC. *See* Dendritic cell
 DC2, 108
 DCAL-1, 462
 DCAR, 462
 DCIR, 462
 DC-SIGN, 85, 286, 379, 458, 460, 462, 464–465, 551, 565, 580
 Dcw1, 151
 Decay accelerating factor, 152–153, 620
 Decorin, 219, 221
 Dectin-1, 456, 460
 Dectin-2, 462
 Degree of polymerization (DP), 542–543
 Delta, 156
 Dengue virus, 507–509, 509f
 Dendritic cell (DC). *See also* DC-SIGN
 CCR7, 85
 CD206, 427
 Cd1d, 137
 CLEC-2 role, 464
 C-type lectins, 463f, 465
 DCAL-1, 462
 galectin-1 function, 500
 markers, 480
 Dental caries, 561, 617
 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid, 772
 2-deoxy-D-glucose, 741
 3-deoxy-3-fluoro-D-glucosamine, 741
 2-deoxy-2-fluoro-L-fucose, 740f
 4-deoxy-4-fluoro-N-acetylglucosamine, 741
 6-deoxyhexose, definition, 8
 Deoxymannonojirimycin, 110, 743f
 Deoxynojirimycin, 743f, 744
 Deoxynorleucine (DON), 261
 Dermatan sulfate (DS)
 cancer changes, 638
 composition, 220
 degradation, 592f
 degradation defects, 591
 history of study, 217
 structure, 11, 37
 synthesis, 227f
 Desbuquois dysplasia, 608
 Deuterostomes
 evolutionary background, 365–366
 model systems. *See* Mouse models; Sea urchin; *Xenopus laevis*; Zebrafish

- Dfg5, 151
 DG42, 206, 544
 DGDG. *See* Digalactosyldiacylglycerol
 DHDDS, 612
 Diabetes mellitus, 261–262, 617–618
 Diacylglycerol (DAG), 284–286
 Diatonic dystrophy (DTG), 609
 DIC. *See* Disseminated intravascular coagulation
Dictyocaulus viviparus, 346, 579
Dictyostelium, 240, 247, 258
Dictyostelium discoideum, 377
 Diet, metabolic disease management, 776–777
 Digalactosyldiacylglycerol (DGDG), 242, 332, 333f
 Dihydroxyacetone, structure, 22f
 Di-*N*-acetyllegionaminic acid, 200
 Di-*N*-acetylpsudaminic acid, 200
Dioclea grandiflora, 434
Dirofilaria immitis, 346, 571t, 579
 Disialyl Lewis a, 637
 Dispersin B (DspB), 562
 Disseminated intravascular coagulation (DIC), 460, 624
 Dissociation constant. *See* Glycan recognition
 DLL1, 156
 DLL3, 156
 DLL4, 156
 Dlp, 360
 D-mannosamine, 740f
 DMAP, 446
 DMB, 195
 DNA, glycosylation, 238
 DnaK, 235
 DNase I, 452
 DNAX, 477
 DNGR-1. *See* CLEC9A
 Doa10, 534
 Dolichol, 65, 107f, 612
 Dolichol-P, 65, 104–107, 106f, 303
 Dolichol-P-glucose, 57, 106
 Dolichol-P-mannose, 106, 152, 670
Dolichos biflorus, 170, 436
 DOLK, 607, 612
 DON. *See* Deoxynorleucine; 6-diazo-5-oxo-L-norleucine
 Donath–Landsteiner test, 621
 Dowling–Degos disease type 2, 158
 Dowling–Degos disease type 4, 159
 DP. *See* Degree of polymerization
 DPAGT1, 106
 D-PDMP, 746
 DPM1, 607
 DPM2, 607
 DPM3, 607
 Dpp, 359–361
 DPY-19, 163
 DrGRIFIN, 493
 D-ribitol-5-phosphate cytidyltransferase (CRPPA), 162
Drosophila melanogaster, 99, 113, 200, 269
 galectins, 493
 genes in glycan synthesis or function, 352t–354t
 history of study, 349–350
 morphogen signaling and organ size control, 359–360
 neural development, 360
 N-glycan processing mutants, 355f
 O-glycan diversity, 356f
 Notch, 157–158, 160, 357–358, 358f
 S2 cell glycoengineering, 763
 stem cell niche proteoglycans, 360
 DS. *See* Dermatan sulfate
 DSA, 647f
 DSE1, 226
 DSE2, 226
 DspB. *See* Dispersin B
 DTG. *See* Diatonic dystrophy
 DXD motif, 72, 74
 DXH motif, 122
- E**
 E2, 534
 E3, 534, 537
 EAE. *See* Experimental allergic encephalomyelitis
 EBA-140, 573
 EBA-175, 572–573
 EBA-180, 573
 EBL proteins, 572–573
 Ebola virus, 465, 763
 4E-BP1, 260
 EBR1, 366
 EBV. *See* Epstein–Barr virus
 E-cadherin, 642
 Ecdysteroid glucosyltransferase (EGT), 97
Echinococcus granulosus, 571t, 579
 EC number. *See* Enzyme Commission number
 EDEM2, 534
 EDEM-3-CDG, 605
 EET. *See* Enzyme enhancement therapy
 EF-P, 234
 EGF. *See* Epidermal growth factor
 EGFR. *See* Epidermal growth factor receptor
egh, 362–363
 EGT. *See* Ecdysteroid glucosyltransferase
 Ehlers–Danlos syndrome, 608
 eIF2, 260
 eIF4E, 260
 Elaprase, 597
 Electron microscopy. *See* Cryo-electron microscopy; Transmission electron microscopy
 Electron transfer dissociation (ETD), 700–701, 713–714
 Elf-1, 260
 Eliglustat, 746, 777
 ELISA. *See* Enzyme-linked immunosorbent assay
 EMT. *See* Epithelial-to-mesenchymal transition
Encephalitozoon cuniculi, 98
 Endo β 1-4-xylanase Xyn10A, 428
 Endoglycan, 470
 Endoglycosidase
 definition, 13
 endoglycosidase F1, 105
 endoglycosidase F2, 105, 677, 678t
 endoglycosidase F3, 105
 endoglycosidase H, 105, 677, 678t, 680, 699
 endoglycosidase II, 734
 glycan analysis, 678t
 Endomucin, 470
 Endo-N, 190
 Endo-N-acetylglucosaminidase (EndoT), 765
 Endoplasmic reticulum (ER)
 glycosphingolipid synthesis, 133
 glycosylation, 12–13, 44, 46, 53
 hyaluronan synthesis, 207
 lectins, 378
 misfolded glycoproteins, 82
 nucleotide sugar transporters, 61–63, 63t
 protein folding quality control machinery and viability, 536–537
 O-glycosylation reactions, 535–536
 stress, 88
 Endoplasmic reticulum–associated degradation (ERAD), 530, 534, 537, 545
 Endopolygalacturonase (EPG), 540
 Endosome, 135, 208, 378, 380, 422, 449, 450f, 452, 458, 460f, 467, 589, 595
 Endosulfatase, 46, 228
 EndoT. *See* Endo-N-acetylglucosaminidase
 Energy, glycan renewable energy, 798–799, 807
 ENGase, 247
Entamoeba histolytica, 425, 513–514, 569, 570t, 577, 578f
Enterobius vermicularis, 571t
Enterococcus faecalis, 97
 Enzymatic synthesis. *See* Chemoenzymatic synthesis, glycans
 Enzyme Commission (EC) number, 95
 Enzyme enhancement therapy (EET), 596
 Enzyme-linked immunosorbent assay (ELISA)
 enzyme assays, 659
 glycan-binding protein studies, 396–397, 519
 Enzyme replacement therapy (ERT), 449–451, 596–597, 777
 EOGT, 47, 160, 252, 258, 357
 EPax, 97
 EPG. *See* Endopolygalacturonase
 E-PHA, 646, 647f, 652–653, 658
 Epidermal growth factor (EGF), 84
 EGF1, 157
 EGF5, 157
 EGF8, 158
 EGF12, 157, 158
 EGF16, 160

- Epidermal growth factor receptor (EGFR), 94, 136–137, 635
- Epidermal growth factor repeats
Notch, 156, 371
- O-glycans
O-fucose glycans, 157–158
O-GlcNAc glycans, 160, 252
O-glucose glycans, 158–160
overview, 156–157
structure, 156–157, 157f
- 4epi-di-*N*-acetyllegionaminic acid, 200
- 8epi-di-*N*-acetyllegionaminic acid, 200
- 8epi-di-*N*-acetylpsuedaminic acid, 200
- 8-epi-legionaminic acid 201f
- Epithelial-to-mesenchymal transition (EMT), cancer stem cell glycosylation changes, 641–642
- EPO. *See* Erythropoietin
- EPS. *See* Exopolysaccharide; Extracellular polysaccharide
- Epstein–Barr virus (EBV), 472, 605, 621
- Equilibrium dialysis, glycan-binding protein studies, 390–391
- ER. *See* Endoplasmic reticulum
- ERAD, 605
- ERGIC-53, 363, 433, 437–438, 533, 536
- ERGL, 437–438
- ERK, 486
- ERp57, 531
- ERT. *See* Enzyme replacement therapy
- Erythropoietin (EPO), 772, 774, 776
- Escherichia coli*
adhesins, 378–379
enteropathogenic, 561
enterotoxin, 138
glycoengineering, 760
glyconanomaterials, 792
hyaluronan synthase, 206
K1, 97, 190, 273, 294, 488, 556
K5, 273
K99, 190, 510–511
LT-1, 179
O-antigens, 39
P fimbriae lectins, 623
pili, 509f, 560, 788
urinary tract infection, 623
- E-selectin (CD62E), 125, 137, 197, 466f, 469–470, 553, 616–617, 636, 642, 782f
- ETD. *See* Electron transfer dissociation
- Ethanol, production, 798
- Ethanolamine phosphate (EtNP), 78, 142–143, 362
- Ethanolamine phosphate transferase-1 (EtNP-1), 147
- Ethanolamine phosphate transferase-2 (EtNP-2), 147
- Ethanolamine phosphate transferase-3 (EtNP-3), 147
- Ethanolamine phosphoesterase-1, 148
- EtNP. *See* Ethanolamine phosphate
- EtNP-1. *See* Ethanolamine phosphate transferase-1
- EtNP-2. *See* Ethanolamine phosphate transferase-2
- EtNP-3. *See* Ethanolamine phosphate transferase-3
- ets-1, 641
- Euonymus europaeus*, 424
- EW29, 425
- EUROCarbDB, 708, 711
- EXM. *See* Extracellular matrix
- Exoglycosidase, definition, 13
- Exopolysaccharide (EPS), 39, 280, 292, 293f, 294, 305, 722, 723f
- Exosome, 152, 481
- Experimental allergic encephalomyelitis (EAE), 480
- Ext1*, 344, 359, 371
- EXT1, 68, 225, 670
- EXT1*, 602t, 608–609
- Ext2*, 359, 371
- EXT2, 225
- EXT2*, 608–609
- EXTL2, 68
- EXTL3, 71, 225
- Extracellular matrix (ECM)
hyaluronan function, 208–210
prospects for glycan studies, 811
proteoglycan function, 218–220
- Extracellular polysaccharide (EPS), 561–562
- ## F
- Fabry disease, 587t, 593, 596–597, 743, 777
- Factor H, 197–198
- Factor IIa, 619
- Factor IX, 157
- Factor V, 437, 536
- Factor VII, 157
- Factor VIII, 437, 536
- Factor Xa, 619
- FADD, 237
- FAK. *See* Focal adhesion kinase
- FAM20B, 182, 608
- Fasciola hepatica*, 571t
- Favin, 435f, 436
- FaxGuDFSA, 750
- FBNI*, 614
- Fc, 551
- Fc receptor, 622–623
- FCMD. *See* Fukuyama congenital muscular dystrophy
- FCSK*, 612
- fdl*, 354
- FDL, 763
- Feedstock, production, 799
- Ferdinand, Carl, 3f
- Ferroplasma acidophilum*, 301
- FGE*, 591
- FGF. *See* Fibroblast growth factor
- FGFR. *See* Fibroblast growth factor receptor
- FHA. *See* Filamentous hemagglutinin
- Fibrillin, 614
- Fibrinogen, abnormal glycosylation, 620
- Fibroblast growth factor (FGF), 377
FGF1, 523
FGF2, 181, 190, 423, 523, 524f, 640, 666
- FGF23, 126, 552, 607, 767
heparin interactions, 523–524
- Fibroblast growth factor receptor (FGFR), 523, 545
- Fibromodulin, 221
- Ficolins, 379
- Filamentous hemagglutinin (FHA), 561
- Fimbriae, 509–511, 514, 560f
- FimH, 510f, 623
- Fischer, Emil, 3f, 22, 308, 404
- Fischer projection
conversion to chair conformation, 26f
conversion to Haworth projection, 25f
monosaccharide structure, 22f, 23–24, 23f
- Fischer–Tropsch synthesis, 798
- FKRP. *See* Fukutin-related protein
- FKRP*, 607
- FKTN. *See* Fukutin
- Flmg glycosyltransferase, 246
- Fluorescence polarization, glycan-binding protein studies, 395
- 3-fluorosialic acid, 741
- 6-fluoro-UDP-Galf, 740f
- Focal adhesion kinase (FAK), 213, 545
- Follicle-stimulating hormone (FSH), 176
- Fondaparinux, 619
- Foot-and-mouth disease virus, 798
- Forkhead, 260
- Forssman antigen, 134, 176
- frc*, 364
- Fringe, 83, 358
- fringe*, 158
- Frontal affinity chromatography, 392
- Fructoaldolase (Aldolase B), 776
- Fructose-6-phosphate, 56
- FSH. *See* Follicle-stimulating hormone
- FSP. *See* Fucose sulfate polymer
- F-spondin, 161
- FtsK1, 235
- FtsY, 235
- FtsZ, 235
- FUCA2, 566
- Fucoidans, 332
- Fucose
glycosylation precursor metabolism, 58
synthesis defects, 611–612
- Fucose sulfate polymer (FSP), 366
- Fucosidase, 566, 586t, 588, 678t
- Fucosidosis, 586t
- Fucosyltransferase III–VII, 68
- Fukutin (FKTN), 162, 607
- Fukutin-related protein (FKRP), 162
- Fukuyama congenital muscular dystrophy (FCMD), 607
- Fullerene, glyconanomaterials, 790
- Fungi. *See also* Yeast
basidiomycetes diversity, 315
cell wall, 308–309, 309f
glycolipids, 313
glycosylation of proteins, 310–311, 310f, 311f, 312f, 313
history of study, 308
model systems, 313–314

- Fungi (*Continued*)
 pathogens, 315–318
 R-type lectins, 425
Fusobacterium nucleatum, 562
 FUT1, 125, 168–169, 172, 175, 340, 342
 FUT2, 125, 168–169, 172, 341
 FUT3, 172
 FUT4, 173
 FUT5, 173
 FUT6, 173, 340, 342
 FUT7, 173, 641
 FUT8. *See* α 1-6 fucosyltransferase
 FUT8-CDG, 605
 FUT9, 173
 FutA, 566
 FutB, 566
 Fuct-III, 658
 Fuct-IV, 470
 Fuct-VII, 470
- G**
- GA1, 425
 GA2, 594
 GAA, 586
 GAG. *See* Glycosaminoglycan
 GAG-DB, 712t, 715
 Galactofuranose, 59
 Galactokinase (GALK), 610
 Galactose
 glycosylation precursor metabolism, 58–59
 synthesis defects, 610–611
 Galactose-1-kinase, 60
 Galactosemia, 776
 Galactose-1-phosphate uridyltransferase (GALT), 610–611
 Galactose-6-sulfate sulfatase, 591
 Galactosialidosis, 586t
 Galactosidase. *See* *specific galactosidases*
 Galactosylceramide (GalCer), 129, 130f, 131, 133–134, 136
 Galactosyltransferase. *See* *specific galactosyltransferases*
 Galafold, 740f, 743f, 744
 Gal α 1-3Gal, 175–176, 175f
Galanthus nivalis, 646
Galanthus nivalis agglutinin (GNA), 646, 789
 GalCer. *See* Galactosylceramide
 GALE, 668f
 Galectin, 96, 167, 247, 363. *See also* *specific galectins*
 evolution, 493–494
 functions
 cell adhesion, 497f
 development and regeneration, 498–499
 apoptosis, 499
 cancer, 499
 immune response and inflammation, 499–500
 adipogenesis, 500
 infection, 500–501
 glycan ligands, 496–498
 history of study, 491–492
 overview, 492–493, 492f
 species distribution, 493
 structure, 494–496
 synthesis and export, 498
 Galectin-1, 493–496, 495f, 496f, 498–501
 Galectin-2, 493–494, 499
 Galectin-3 (CBP35), 247, 492–494, 498–499, 501
 Galectin-4, 493–494, 497–500
 Galectin-5, 493–494
 Galectin-6, 494
 Galectin-7, 493–494, 498–499
 Galectin-8, 247, 493–494, 497, 500
 Galectin-9, 493–494, 498, 500
 Galectin-10, 493–494
 Galectin-11, 493
 Galectin-12, 493–494, 499–500
 Galectin-13, 493–494
 Galectin-14, 493–494
 Galectin-15, 493
 GALK. *See* Galactokinase
 GalNAc. *See* N-acetylgalactosamine
 GalNAc-O-benzyl, 125
 GalNAc transferase, 70
 GALNT, 100, 121–123, 125–126, 767
 GALNT1, 126
 GALNT2, 126, 607
 GALNT3, 126, 552, 607
 GALNT7, 101
 GALNT11, 126, 624
 GAL3ST4, 125
 GALT. *See* Galactose-1-phosphate uridyltransferase
 GALT-1, 340, 342
 Gal α 1-3Gal antigen
 clinical significance, 175–176
 synthesis, 175
 GANAB. *See* α -glucosidase II
 Ganglioside, definition, 11, 131. *See also* *specific gangliosides*
 GAPDH, 238
 Gas chromatography/mass spectrometry. *See* Mass spectrometry
 GAS. *See* Group A Streptococcus
 Gaucher disease, 130, 138, 587t, 592, 596–597, 746, 777
 gB, 508
 Gb3, 425–426, 513
 GBA. *See* Acid glucosylceramidase
 GBGT1, 176
 GBS. *See* Group B Streptococcus
 gC, 508
 GCN5, 257
 GCNT1, 124
 GCNT2, 168
 GCNT3, 124, 168
 GCNT4, 124
 GCS. *See* Glucosylceramide synthase
 gD, 508
 GD1, 641
 GD1a, 137–138, 483, 731
 GD1b, 132, 137, 439
 GD2, 134, 138, 637, 642, 780
 GD2 synthase, 137
 GD3, 132, 134, 139, 635, 637
 GD3 synthase. *See* ST8SIA1
 GDE2, 152
 GDNFR- α . *See* Glial-derived neurotrophic factor receptor- α
 GDP-arabinose, 63
 GDP-2-deoxy-2-fluoro-fucose, 741
 GDP-2-deoxyglucose, 741
 GDP-fucose, 58, 63–64, 611–612
 GDP-4-keto-6-deoxy-glucose, 58
 GDP-4-keto-6-deoxy-mannose, 58
 GDP-mannose, 58, 63, 106, 163
 GDP-mannose-4,6-dehydratase (GMD), 741
 Gel electrophoresis, glycans, 676, 679, 695
 GELATO, 713
 Gellan, 40
 Genomes OnLine Database (GOLD), 94
 Gentiobiose, 30, 30f
Geodia cynodinium, 493
 Germline stem cell (GSC), 361f
 GFAT. *See* Glutamine–fructose-6-phosphate transaminase
 GftA, 246
 GftB, 246
 Gg4, 641
 GGDB. *See* GlycoGene Database
 Ggta1, 658
 GGTA1, 175
Giardia lamblia, 258, 513, 570t, 580
 Gingivitis, 617
 GIPL. *See* Glycoinositol phospholipid
 GLAD, 97, 710t, 715
 GlcCer. *See* Glucosylceramide
 GLCE, 226
 GlcNAc. *See* N-acetylglucosamine
 GlcNAc 3-O-sulfotransferase 1, 47
 GlcNAc-1-P, 106, 371
 GlcNAc-1-phosphodiester α -N-acetylglucosaminidase, 47
 GlcNAcT-I, 50, 341, 350–351, 352t, 355f, 761. *See also* GnT-I, MGAT1
 GlcNAcT-II, 50, 350, 761, 763. *See also* GnT-II, MGAT2
 GlcNAcT-III, 350, 764. *See also* GnT-III, MGAT3
 GlcNAcT-IV, 350. *See also* GnT-IV, MGAT4
 GlcNAcT-V, 745t. *See also* GnT-V, MGAT5
 GlcNAc-phosphotransferase. *See* N-acetylglucosamine-1-phosphotransferase
 GlcNAc-P-serine, 77
 GlcNAc-P-T, 447, 451, 453
 GlcNAcstatin, 744f, 745
 GlcNAc-T, 147, 658
 GlcNAcT. *See* N-acetylglucosaminyltransferase
 Glial-derived neurotrophic factor receptor- α (GDNFR- α), 151
 Glide, 413
 Glioma, 642

- Globo-H, 773f, 780
 Globopentosylceramide. *See* Forssman antigen
 Globotriaosylceramide, 138
 Glucocerebrosidase, 592, 597, 746
 Glucomannan, 321f, 326, 779
 Glucopyranose, structure, 23f
 Glucosamine, 520f, 779
 Glucosamine:fructose aminotransferase pathway, 618
 Glucosamine-6-phosphate, 59
 Glucose
 glycosylation precursor metabolism, 56–57
 structure, 5
 Glucose-1-phosphate, 56, 58
 Glucose-6-phosphate, 56
 Glucose-1-phosphate phosphodiesterase, 244
 Glucose phosphotransferase, 244
 Glucose transporter (GLUT), 54–55
 GLUT1, 54–55
 GLUT2, 55, 552
 GLUT4, 55, 257
 GLUT5, 55
 Glucosidase II, 453
 Glucoside α 1-3 xylosyltransferase, 160
 Glucosylceramide (GlcCer), 130–131, 134, 136, 138, 553, 729–730, 730f
 Glucosylceramide synthase (GCS), 729–730, 730f, 746
 Glucuronic acid
 conformation, 520f
 glycosylation precursor metabolism, 57
 insects, 357
 Glucuronic acid-2-sulfatase, 590
 Glucuronoxylan, 321f, 328
 Glustat. *See* Voglibose
 GLUT. *See* Glucose transporter
 Glutamine–fructose-6-phosphate transaminase (GFAT), 59, 64, 262
 Glutaminyglycan, 300
 GLYCAM, 413–415, 688, 712t
 GlyCAM-1, 470
 GLYCAM-Web, 715
 Glycan. *See also specific glycans*
 biological functions
 cell–cell interactions, 82–84
 cell–microbe interactions, 84
 diverse roles of same glycan, 85
 experimental alteration, 81
 junk glycans, 86
 mimicry, 84–85, 273
 overview, 79–81, 80f
 structural functions, 81–82
 terminal sequences and modifications, 86
 tools for study, 87–90, 87f
 classes, 10–12, 10f
 conjugation, 33
 diversity
 bacteria and Archaea, 273, 301–302
 evolutionary forces driving diversity, 276
 glycosaminoglycan, 271
 glycosphingolipid, 271
 interspecies and intraspecies diversity in glycosylation, 273–275
 model organisms for study, 275
 molecular mimicry by pathogens, 273
 N-glycan, 266–269
 nucleocytoplasmic glycans, 271–272
 O-glycan, 270–271
 overview, 265–266
 sialic acid, 269–270
 structural glycan, 272
 diversity
 biological roles, 16
 structures, 8
 glycocalyx, 6–7
 medicine and biotechnology, 17
 microarrays, 96–97, 398f
 modifications
 donors, 64–65, 64t
 overview, 8
 nanotechnology, 17
 O-GlcNAc glycan. *See* O-GlcNAc glycan
 physiological functions
 airway, 551–552
 cardiovascular system, 551
 development, 550
 endocrinology, 552
 gastroenterology, 552
 hematology, 550–551
 hepatology, 552–553
 immunology, 551
 musculoskeletal system, 553
 nephrology, 553
 neurobiology, 553–554
 oral biology, 552
 reproduction, 549–550
 skin, 553
 protein linkages, 10–11
 salvage pathways, 55
 structural analysis. *See* Structural analysis, glycans
 Symbol Nomenclature for Glycans, 8, 40f
 synthesis
 biosynthesis. *See specific glycans*
 chemical synthesis. *See* Chemical synthesis, glycan
 chemoenzymatic synthesis. *See* Chemoenzymatic synthesis, glycans
 overview, 12
 terminology, 21–22
 turnover and recycling, 50
 GlycanAnalyzer, 713t
 Glycan-binding proteins (GPBs). *See also* Lectin; Sulfated glycosaminoglycan-binding proteins; *specific proteins*
 classification, 375–376
 data analysis software tools, 714–715
 functions
 cell adhesion, 378–379
 immunity and infection, 379
 protein trafficking, targeting, and clearance, 377–378
 gene families, 96–97
 genomics, 94
 glycan recognition. *See* Glycan recognition
 intrinsic versus extrinsic, 80
 ligand terminology, 385
 microbiome, 813
 nematodes, 344–345
 research applications, 88–89
 structural families, 380, 381f, 382–383
 Glycan foraging, 552
 Glycan microarray, glycan-binding protein studies, 397–398, 398f
 Glycan Microarray Database (GlyMDB), 715
 Glycan Miner, 715
 Glycan–protein interactions. *See* Glycan-binding proteins; Glycan recognition
 Glycan recognition
 binding thermodynamics, 389–390, 389f
 dissociation constant
 definition, 389
 measurement, 390–395
 history of study, 388–389
 overview, 387
 structure studies
 computational modeling
 enzyme substrate docking, 416–417
 heparan sulfate oligomer docking, 414–415
 molecular dynamics, 413–414
 molecular mechanics, 413
 principles, 412–414
 quantum mechanics, 413–414
 cryo-electron microscopy, 411–412
 nuclear magnetic resonance
 bound ligand geometry and ligand interaction surfaces, 408–411
 chemical-shift mapping, 408
 principles, 407–408
 overview, 403–404
 prospects, 417
 X-ray crystallography
 carbohydrate-binding site interactions, 405–406
 databases, 405
 folding in lectins, 406–407
 principles, 405
 symbols and conventions, 8, 9f
 therapeutic targeting
 infection, 781
 selectin-mediated leukocyte trafficking, 781
 tools for study of protein–glycan binding
 affinity chromatography, 391–392, 392f
 affinity co-electrophoresis, 399
 agglutination, 398–399
 atomic force microscopy, 396
 enzyme-linked immunosorbent assay, 396–397
 equilibrium dialysis, 390–391
 fluorescence polarization, 395
 glycan microarray, 397–398, 398f

- Glycan recognition (*Continued*)
 isothermal titration calorimetry, 392–393, 393f
 mass spectrometry, 396
 nuclear magnetic resonance, 396
 precipitation, 399
 recombinant protein expression, 399
 surface plasmon resonance, 393–395, 394f
 valency of interactions, 388–389, 388f
- Glycan-recognizing probe. *See*
 Carbohydrate-binding module;
 Lectin; Monoclonal antibodies to
 glycan antigens
- Glycan signaling
 developmental signaling, 543–545
 glycosaminoglycans, 545
 innate immunity modulation, 546
 overview, 539–540
 plant defense response, 540–542
Rhizobium–legume symbiosis, 543
- Glyceraldehyde, structure, 22f
- Glyco. *See* Glycomics Ontology
- GlycoBase, 714
- Glycobiology
 evolutionary considerations, 16–17
 general principles, 4t–5t
 merging into holistic approach to biology,
 813
 Nobel laureates, 3f
 overview, 1–3
 prospects, 805–813
- Glycocalyx, 6–7, 7f, 811
- Glycoconjugate
 classes, 10–12
 definition, 5, 22
 glycans, 6
- GlycoCT, 708
- Glyco3D, 712t, 715
- Glycodelin A, 276
- Glycodelin S, 276
- Glycodendrimer. *See* Nanotechnology
- GlycoDigest, 713t
- GlycoDomain, 712t
- Glycoengineering
 applications, 767
 bacteria
 N-glycans, 760–761
 O-glycans, 761
 oligosaccharide engineering, 760
 overview, 759
 biotherapeutic glycoproteins, 775t, 776
 goals, 744
 insects
 N-glycans, 763–764
 O-glycans, 764
 overview, 763
 mammalian cells
 Chinese hamster ovary cells, 764–767
 N-glycans, 764–766
 O-glycans, 766–767
 overview, 764
 milestones, 756t–757t
 pathways, 754–755, 755f, 758
- plants
 N-glycans, 762–763
 O-glycans, 763
 overview, 762
- prospects, 768
- techniques in eukaryotes
 genes editing modules, 759f
 knockdown, 758
 knockout and knock-in, 758–759
 overexpression, 758
- yeast
 N-glycans, 761–762
 O-glycans, 762
 overview, 761
- GlycoEpitope, 713t
- Glycoforest, 712t
- Glycogen
 glycosylation precursor metabolism, 56
 structure, 36, 56
- Glycogen synthase, 241, 254t, 257f
- GlycoGene Database (GGDB), 95, 709
- Glycogenin, 240–241
- Glycoglycerolipid, structure, 130
- Glycoinformatics
 data analysis software tools
 glycan attachment sites on proteins,
 715–716
 glycan-binding protein data,
 714–715
 high-performance liquid
 chromatography, 714
 mass spectrometry, 711, 713–714
 nuclear magnetic resonance, 714
 structure modeling, 715
 table, 712t–713t
 data standardization and ontologies,
 709–711
 databases, 708–710, 710t
 drawing of glycan structures, 707–708
 overview, 705
 prospects
 collaboration, 716–717
 glycobiology as part of systems biology,
 716
 structure linking with function, 716
 rationale, 706–707, 706f
- Glycoinositol phospholipid (GIPL), 143,
 574, 577
- Glycolipid
 cell culture synthesis mutants, 671
 degradation defects, 587t
 detection, 677–678
 inhibitors, 746–747
 nematodes, 344–345
 plants, 332–333
- Glycome
 Archaea, 98
 bacteria, 97
 overview, 93–94, 690
 regulation, 101
 relationship to genome and proteome,
 690
 viruses, 97
- GlycomeAtlas, 713t
- Glycomics
 comparative glycomics, 691
 genomics relationship, 100–101
 glycan class characterization, 694
 glycoprofiling, 693–694
 integration into mainstream databases, 813
 overview, 14–15
 prospects, 809
 structural analysis, 694–697
 tools, 691, 692f, 693
- Glycomics Ontology (Glyco), 709, 710t
- Glycomimickry, 84–85
- GlycoMinesStruct, 712t
- GlycoMob, 713t
- GlycoMod, 711, 712t
- Glyconanomaterials. *See* Nanotechnology
- Glycone, glycoconjugate, 5
- Glyconic acid, 27
- GlyConnect, 708, 710t
- Glyconutrient
 chondroitin sulfate, 779
 definition, 779
 glucosamine, 779
 human milk oligosaccharides, 779–780
 sorbitol, 779
 xylitol, 779
- GlycoPAT, 712t, 714
- GlycoPedia, 713t
- GlycopeptideGraphMS, 712t
- GlycoPOST, 710t
- Glycoprotein folding
 calnexin/calreticulin/UDP-glucose
 glycoprotein glycosyltransferase
 cycle
 misfolded glycoprotein removal,
 533–534
 timing of folding, 530–533
 chaperones, 529–530
 cytosolic retrotranslocation of misfolded
 glycoproteins, 534–535
 endoplasmic reticulum quality control
 machinery and viability, 536–537
 O-glycosylation reactions, 535–536
- Glycoproteomics
 glycosylation site mapping, 699
 heterogeneous site glycosylation, 700–701
 limitations and prospects, 702
 overview, 691–693, 692f
 workflow, 693f
- GlycoRDE, 709, 710t
- GlycoRNA, 811
- Glycosaminoglycan (GAG). *See also*
 Proteoglycan; *specific*
glycosaminoglycans
 binding proteins
 classes, 518t
 interaction measurement techniques,
 519t
 overview, 16
 sulfated glycosaminoglycan-binding
 proteins. *See* Sulfated
 glycosaminoglycan-binding
 proteins
 cancer changes, 638–640, 639

- cell culture assembly mutants, 670–671, 670t
- cell signaling, 545
- cellular regulation of structure, 38–39
- composition, 218
- definition, 10
- degradation defects, 587t, 589–592
- detection, 677
- evolutionary variation, 271
- history of study, 217–218
- insects, 359–361
- lyases for analysis, 678t
- nucleus, 244–245
- prospects for study, 812
- protein linkages, 223–225
- secretory granule function, 82
- structure, 11, 37, 220f
- structure–function relationships, 38
- synthesis
- assembly regulation, 228–229
 - chondroitin sulfate, 226–227
 - defects, 608–609
 - heparan sulfate, 226, 228
 - keratan sulfate, 225–226
 - therapeutic applications, 778
- Glycosidase. *See also specific glycosidases*
- catalytic mechanisms, 75f, 76
- family features, 73
- functional overview, 73–74
- gene families, 95
- genomics, 94–95
- inhibitors, 742–744
- invertebrates, 99
- mechanism, 729–730
- modular glycosidases, 100
- mutations, 138
- plants, 98
- research applications, 89–90
- structural analysis of glycans, 679f
- vertebrates, 99
- Glycoscience, prospects
- analytical techniques, 807–808
 - basic and applied research, 805–806
 - ease of study, 810
 - energy, 807
 - enzymology, 809
 - glycomics, 809
 - health and development, 806–807
 - high-throughput analysis, 809–810
 - materials science, 807
 - research questions, 810–813
 - synthesis, 808–809
- Glycoside primer, glycosylation inhibitors, 747–748, 747f
- Glycosidic linkage
- α -linkage, 5, 7
 - analysis
 - mass spectrometry, 682–684
 - position, 681–682 - β -linkage, 5, 7
 - formation, 29
 - stereochemical control in chemical synthesis, 720–721, 720f
- stereoisomers, 30
- torsion angle, 31–32
- GlycoSiteAlign, 713t
- GlyCosmos, 708–709, 710t, 715, 717
- Glycosphingolipid (GSL). *See also specific glycosphingolipids*
- cancer expression, 637
 - classes and nomenclature, 130–131
 - definition, 11
 - degradation
 - defects, 592–594
 - pathways, 135, 593f - discovery, 129–130
 - evolutionary variation, 271
 - glycosphingolipid diversity, 362f
 - insects, 361–363
 - isolation, purification, and analysis, 133
 - membrane microdomains, 135–136
 - nematodes, 337
 - overview, 129–130
 - pathology, 138–139
 - physiological functions, 136–137
 - recycling, 594
 - structure, 130, 130f, 131f
 - synthesis
 - defects, 610
 - pathways, 132–134, 132f
 - trafficking, 134–135
- GlycoStore, 714
- GlycoSuiteDB, 708
- Glycosylation
- Archaea. *See* Archaea
 - bacterial proteins, 290–291
 - carrier lipid synthesis, 65
 - cell biology, 13
 - defects, 15–16
 - developmental changes, 16
 - distribution in nature, 43–44
 - DNA, 238
 - donors, 44–45, 53–54, 54t
 - engineering. *See* Glycoengineering
 - epidermal growth factor repeats. *See* Epidermal growth factor repeats
 - eukaryotes
 - endoplasmic reticulum–Golgi pathway, 44, 46
 - Golgi enzymes
 - localization in Golgi compartments, 47–50
 - topology, 46–47 - mitochondria, 50
 - nuclear and cytosolic glycosylation, 45–46
 - plasma membrane, 46 - experimental alteration, 81
 - genomics, 94–95
 - glycosaminoglycans in nucleus, 244–245
 - inhibitors. *See* Glycosylation inhibitors
 - interspecies and intraspecies differences, 273–275
 - mitochondrial membrane proteins, 241–242
 - monosaccharide precursor metabolism
 - activation and interconversion
 - fucose, 58
 - galactose, 58–59
 - glucose, 56–57
 - glucuronic acid, 57
 - glycogen, 56
 - iduronic acid, 57
 - mannose, 58
 - N-acetylgalactosamine, 60
 - N-acetylglucosamine, 59–60
 - sialic acid, 60
 - xylose, 57–58 - bacteria and plants, 60–61
 - control of precursor pools, 64
 - salvage, 55 - N-glycosylation site prediction in eukaryotes, 104–105
 - nucleocytoplasmic proteins
 - assembly intermediates, 246
 - complex glycosylation
 - glycogenin, 240–241
 - Skp1, 238–240 - enzymes, 247–248
 - evolutionary variation, 271–272
 - examples, 236t–237t
 - glycosyltransferases in nucleus, 244
 - monoglycosylation
 - eukaryotes, 234
 - prokaryotes, 234–235
 - toxins in bacteria, 237–238 - N-glycans, 242–243
 - O-glycans, 244
 - overview, 233–234
 - prospects for study, 248–249
 - secretion, 245–246
 - topography of glycosylation, 235f
 - prokaryotes, 46
 - regulation of glycan extensions
 - poly-N-acetylactosamines, 167–168
 - type-1 glycan units, 166, 167f
 - type-2 glycan units, 166, 167f - site-specific structural diversity, 12
 - tools for study, 14
 - variations within and between species, 85–86
- Glycosylation inhibitors
- acceptor and donor analog rational design, 745–746, 745t
 - advantages, 739–740
 - biosynthetic precursor inhibitors, 740–742
 - chain terminators, 748–749
 - glycolipid inhibitors, 746–747, 746f
 - glycosidase inhibitors, 742–744
 - glycoside primers, 747–748, 747f
 - glycosylphosphatidylinositol anchor inhibitors, 746–747
 - glycosyltransferase inhibitors, 745t
 - O-GlcNAc-processing enzyme inhibitors, 744–745
 - overview, 88
 - rational design, 749–750

- Glycosylinositol-phosphorylceramides, 333–334
- Glycosylphosphatidylinositol (GPI) anchor
cancer expression, 637–638
cell biology applications, 151
cell culture biosynthesis mutants, 669–670, 670t
chemistry, 144
definition, 11, 141
detection, 679
discovery, 141–142
diseases, 152–153
functions, 151–152
inhibitors, 746–747
membrane properties of anchored proteins, 150–151
plants, 330
Plasmodium, 572–573
protein diversity, 142
structure
 non-protein-linked structures, 143
 protein-linked structures, 142–143, 143f
synthesis
 pathways, 78, 144–149, 145f, 147t–148t
 defects, 609
topology 146f
trafficking, 149–150
- Glycosylphosphatidylinositol transamidase, 148
- Glycosyltransferase. *See also specific glycosyltransferases*
acceptor substrate protein recognition, 69–71
Archaea, 98
bacteria, 97
catalytic mechanisms, 74–76, 75f
chemoenzymatic synthesis of glycans, 730–732, 733f
gene families and fold types, 72–73, 95
general properties, 67–68
genomics, 94–95
glycoengineering, 760
intrinsic function limitations, 275–276
invertebrates, 99
kinetic mechanisms, 76–77
mechanism, 729–730
modular glycosyltransferases, 100f
nematodes, 339–341
plants, 98, 320, 324
specificity, 68–69, 69f
vertebrates, 99
viruses, 97
- Glycosynthase, chemoenzymatic synthesis of glycans, 732–737
- GlycoWorkBench, 712t, 713t
- GlycReSoft, 712t, 714
- GLYDE-II, 708
- GlyGen, 708, 710t, 715
- GlyMDB. *See* Glycan Microarray Database
- GLYMMR, 715
- Glypican, 222–223, 245
- Glyset. *See* Miglitol
- GlySpace Alliance, 707
- GlyTouCan, 709–711
- GlyVicinity, 712t
- glyXtoolMS, 712t
- GM1, 131, 134, 137–138, 179, 197, 389, 511, 618, 625
- GM1b, 425
- GM2, 130, 132, 134, 138–139, 178f, 193, 596, 641, 780
- GM3, 131, 134, 137–138, 373, 481, 610, 637
- GM4, 178
- GMD. *See* GDP-mannose-4,6-dehydratase
- GM1 gangliosidosis, 586t, 587t
- GM2 gangliosidosis, 586t, 594
- GMI-1070. *See* Rivipansel
- GM2 synthase, 137
- GMPPB, 607
- GNA. *See* *Galanthus nivalis* agglutinin
- GNE, 60, 64, 191, 550, 602t, 611, 622, 624, 776
- GNE myopathy, 602t
- GNOME, 710t
- GNPTAB, 446, 446f
- GNPTG, 112, 446, 446f
- GnT-I, 330, 469. *See also* GlcNAcT-I, MGAT1
- GnT-II, 330. *See also* GlcNAcT-II, MGAT2
- GnT-III, 633. *See also* GlcNAcT-III, MGAT3
- GnT-IV. *See also* GlcNAcT-IV, MGAT4
- GnT-V, 632, 745t. *See also* GlcNAcT-V, MGAT5
- GNTAB, 112
- Goblet cell, 369, 551–552, 627
- GOLD. *See* Genomes OnLine Database
- Gold nanoparticle (AuNP), 786–788, 788f
- Golgi apparatus
enzymes in glycosylation
 localization in Golgi compartments, 47–50, 48f
 topology, 46–47, 48f
glycosphingolipid synthesis, 133
glycosylation, 12–13, 44, 46, 53
homeostasis defects, 612–613, 613f
hyaluronan synthesis, 207
nucleotide sugar transporters, 61–63, 63t
- Gottschalk, Alfred, 505
- GP Finder, 714
- gp41, 565
- gp120, 497, 565
- GPAA1, 609
- GPBs. *See* Glycan-binding proteins
- GPI anchor.
See Glycosylphosphatidylinositol anchor
- GPQuest, 712t, 714
- GQ1b, 625
- Graphene, glyconanomaterials, 791–792
- Grb2, 488
- Greb1, 234
- GRIFIN, 493
- GRITS, 712t, 713t
- GROMOS, 413
- Group A Streptococcus (GAS), 556, 558, 561
- Group B Streptococcus (GBS), 273, 481, 486–487, 489, 556–557, 560
- Grp78, 531, 536
- GRP78, 437
- GSC. *See* Germline stem cell
- GSI-B4, 658
- GSK3 β , 256
- GSL. *See* Glycosphingolipid
- GSL-II, 658
- GT1b, 130f, 137, 439, 483
- GT1c, 134
- GT2, 134
- GT3, 132
- GT-A, 73f
- GT-B, 73f
- GT-C, 73f
- 4-guanido-DANA, 749f
- GuCal, 713t
- Guillain–Barré syndrome, 138, 425, 625
- Gut microbiota
glycan-based interactions with host, 566
human milk oligosaccharide metabolism, 35
- Gwt1, 153
- GXYLT1, 160
- GXYLT2, 160
- GYLT1B, 606f
- ## H
- HA. *See* Hemagglutinin
- HABP1, 211
- HADDOCK, 414
- Haemonchus contortus*, 346, 571t, 579, 579f
- Haemophilus influenzae*, 41, 291, 486, 556–558, 561, 780
- H blood group antigen, 169f, 659
cross-matching, 172
genetics, 169–170
LT-1 recognition, 179
synthesis, 168–170, 170f
tissue distribution of determinants, 170
- Hairy cell leukemia, 482
- Haloarcula hispanica*, 305
- Halobacteriaceae*, 428
- Halococcus morrhuae*, 300
- Halocynthia roretzi*, 369
- Haloferax volcanii*, 303f, 305
- Halomucin, 301
- Haloquadratum walsbyi*, 301
- HAP1 cell. *See* Cell culture glycosylation mutants
- HAPLN-1, 209
- HAPLN-4, 209
- HappyTools, 713t
- HARE, 208, 211–213
- HAS, 68, 207
- Has1*, 208
- Has2*, 208
- HAS2, 207, 210
- Has3*, 208
- HAS3, 207
- hasA*, 207
- HAT. *See* Histone acetyltransferase

- Haworth, Walter, 3f, 308
Haworth projection
 conversion to chair conformation, 26f
 monosaccharide structure, 25f
HBP. *See* Hexosamine biosynthetic pathway
HCC. *See* Hepatocellular carcinoma
HCD, 713–714
HCELL. *See* CD44
HDL. *See* High-density lipoprotein
HE. *See* Hemagglutinin-esterase
Helicobacter pullorum, 291
Helicobacter pylori
 adhesion, 179, 196
 blood type and susceptibility, 172–173
 DC-SIGN signaling, 464
 glycan inhibitors, 125
 gut interactions, 566
 mucin protection, 552
 O-antigens, 39
 treatment of infection, 618
Helicobacter succinogenes, 291
Helicobacter winghamensis, 291
Helix pomatia, 120
Helix pomatia agglutinin (HPA), 647
Hemagglutinin (HA), 179, 196, 419, 428, 431, 506–508, 507t, 508t, 564, 772
Hemagglutinin-esterase (HE), 563
Hematopoietic stem cell transplantation (HSCT), 596–597
Hemiacetal, formation, 25
Hemicellulose, 272
 structures, 321f, 326
 synthesis, 329
Hemolin, 477
Hemolysin, 428
HEMPAS, 612
Heparanase, 590, 640
Heparan sulfate (HS)
 acquired anticoagulation, 620
 Alzheimer's disease studies, 625–626
 atherosclerosis role, 617
 cancer changes, 638–640
 cell culture assembly mutants, 670
 cellular regulation of structure, 38–39
 composition, 220
 CSP interactions, 571
 degradation 590–591, 590f
 degradation defects, 590–591
 heparin comparison, 229–230
 herpes simplex virus pathogenesis, 564–565
 insects, 359
 monosaccharide conformations, 37
 nematodes, 337, 343–344
 nucleus, 245
 oligomer docking simulation, 414–415
 protein-losing enteropathy role, 618–619
 SARS-CoV-2 spike protein binding, 518
 structure, 11, 37
 synthesis
 defects, 608–609
 pathways, 47, 226, 228
 systemic lupus erythematosus changes, 624–625
Heparan sulfate lyase, 678t
Heparin, 377
 anticoagulant use, 619, 778
 binding protein interactions
 antithrombin, 521–523
 FGF, 523–524, 524f, 545
 specificity, 521
 composition, 220
 heparan sulfate comparison, 229–230
 history of study, 217
 LMW heparin, 619, 778
 oligosaccharide conformation, 519–520
Heparin-induced thrombocytopenia (HIT), 619
Hepatitis C virus, 465
Hepatocellular carcinoma (HCC), 642
Hepatocyte growth factor (HGF), 640
HER2, 213
Hereditary inclusion body myopathy type II (HIBM-II), 611, 776
Hereditary multiple exocytosis (HME), 602t, 608–609
Herpes simplex virus (HSV), 452, 507–508, 514, 562, 563f, 564–565
HEV. *See* High endothelial venule
HEX-2, 340, 342
HEX-3, 340, 342
Hex A, 247, 745
Hex B, 247, 745
Hex C, 247
Hex D, 247
Hexokinase, 56
Hexosamine, definition, 8
Hexosamine biosynthetic pathway (HBP), 256, 262
Hexose, definition, 8
HGF. *See* Hepatocyte growth factor
Hh, 360
HHV-1. *See* Human herpesvirus 1
HIBM-II. *See* Hereditary inclusion body myopathy type II
Hidden Markov model (HMM), 715
HIF-1 α . *See* Hypoxia-inducible factor-1 α
High-density lipoprotein (HDL), 616
High endothelial venule (HEV), 182, 467, 470
High-performance liquid chromatography (HPLC), 654, 680, 807
 automated glycan assembly, 725
 data analysis software tools, 714
 mass spectrometry coupling, 696–697
 monosaccharide composition analysis, 681
 N-glycans, 105
 O-GalNAc glycans, 120
High-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD), 681
High-throughput analysis, prospects, 809–810
HILIC. *See* Hydrophilic interaction liquid chromatography
Hint-1, 369
Hint-2, 369
Hirschsprung disease, 152
Histone acetyltransferase (HAT), 257
HIT. *See* Heparin-induced thrombocytopenia
HIV. *See* Human immunodeficiency virus
HME. *See* Hereditary multiple exocytosis
HMGB-1, 198
HMM. *See* Hidden Markov model
HMMR, 213
HMOs. *See* Human milk oligosaccharides
HMW1C, 246
HNK-1, 182, 478, 625, 748
Homogalacturonan, 322f, 327–328
Homologous recombination (HR), 759, 764
HPA. *See* *Helix pomatia* agglutinin
HPAEC-PAD. *See* High-pH anion-exchange chromatography with pulsed amperometric detection
HPLC. *See* High-performance liquid chromatography
HR. *See* Homologous recombination
HR23B, 534
H-ras, 641
Hrd1p, 534
Hrd3p, 534
HS. *See* Heparan sulfate
HS2ST, 226
Hs2st, 359
Hs6st, 359
HS3T1, 226
HS3T6, 226
HS6T1, 226
HS6T3, 226
HSCT. *See* Hematopoietic stem cell transplantation
hsp60, 529
HSP-70, 489
hsp70, 529
HSQC, 408, 685–687, 686f
HSV. *See* Herpes simplex virus
HSV-1, 562, 564–565
HTLV-1, 641
Htm1p, 534
Human Glycoproteomics Initiative, 702, 714
Human herpesvirus 1 (HHV-1), 564
Human immunodeficiency virus (HIV), 258, 272, 410, 410f, 412f, 464, 480–481, 497, 501, 507–509, 537, 562, 563f, 565–566, 735, 744
Human milk oligosaccharides (HMOs)
 glyconutrients, 779–780
 gut microbe metabolism, 35
 phenotypes, 35
 signaling, 544
 structure, 35, 544
 synthesis, 174–175
Human Proteome Organization-Proteomics Standards Initiative, 707
Humicola insolens, 734

- Hummel–Dreyer method, 391
 Hunter disease, 587t
 Hurler syndrome, 587t, 589, 597
 Hurler–Scheie syndrome, 587t, 589, 597
 HYAL1, 208, 589
 HYAL2, 208
 HYAL3, 208
 HYAL4, 208
 Hyaluronan
 bacteria capsules, 213
 binding proteins with link modules, 209f, 211–212, 211f
 biophysical properties, 206
 cancer expression, 638
 chondroitin sulfate complex, 210f
 clinical applications, 214
 composition, 220
 degradation defects, 589
 evolutionary perspective, 205–206
 extracellular matrix function, 208–210
 heart development role, 551
 history of study, 205
 signaling, 212–213, 212f
 structure, 11–12, 206f
 synthesis, 206–207, 207f
 therapeutic applications, 778
 turnover, 207–208
 Hyaluronic acid, structure, 37
 Hyaluronidase, 589
 Hydrogen deuterium exchange mass spectrometry, 396
 Hydrophilic interaction liquid chromatography (HILIC), 694, 696
 Hydroxyl group, monosaccharide
 deoxygenation, 30
 esterification, 29
 methylation, 29
 5-hydroxymethylcytosine, 97
 Hypoxia-inducible factor-1 α (HIF-1 α), 641
- I**
- i blood group, 167–168, 168f
 I blood group, 167–168, 168f
 ICAM. *See* Intercellular adhesion molecule
 I-cell disease, 443–444, 444f, 447, 584, 597, 599
 Ichthyosis, 138
 IDGF. *See* Imaginal disc growth factor
 IdID cell, 667–668
 IdoA. *See* Iduronic acid
 IdoA2S, 519–520
 Iduronic acid (IdoA), 414
 glycosaminoglycans, 38
 glycosylation precursor metabolism, 57
 synthesis, 39
 Iduronic acid-2-sulfatase, 590, 597
 IFN- γ . *See* Interferon- γ
 IgA1, 624
 IGF-I. *See* Insulin-like growth factor I
 IGF-II. *See* Insulin-like growth factor II
 IgG. *See* Immunoglobulin G
 IHABBP4, 211
 IL-1, 558, 616
 IL-1 β , 467, 469
 IL-5, 487
 IL-10, 85, 487
 IL-13, 369
 Imaginal disc growth factor (IDGF), 363
 Imiglucerase, 777
 Immune thrombocytopenia (ITP), 622
 Immunoglobulin A nephropathy, 624
 Immunoglobulin G (IgG), rheumatoid arthritis glycosylation changes, 622–623
 Imperial College Microarray Data Online Portal, 97
 Infectious disease. *See specific diseases and pathogens*
 Influenza, 563–564, 749
 influenza-A, 506–507
 influenza-B, 506–507
 influenza-C, 89
 Influenza virus, 563f
 hemagglutinin, 179, 197, 507t, 508f
 neraminidase, 196, 772
 rational design of inhibitors, 773f
 Inositol acyltransferase, 147
 Inositol deacylase, 148
 Inositolphosphoceramide, 142
 Inotuzumab ozogamicin, 482
 Insects. *See also Drosophila melanogaster*
 chitin, 361
 glycoengineering
 N-glycans, 763–764
 O-glycans, 764
 overview, 763
 glycosaminoglycans, 359–361
 glycosphingolipids, 361–363, 362f
 lectins, 363–364
 N-glycan assembly and diversity, 350–351, 351f, 354–355
 nucleotide sugar transporters, 364
 O-glycan assembly and diversity, 355, 356f, 357–358
 proteoglycan function, 359–360
 Insulin, 257f, 552
 Insulin-like growth factor I (IGF-I), 451
 Insulin-like growth factor II (IGF-II), 448, 451
 Insulin receptor, 84, 136–137, 618
 Intelectin-1, 369, 553
 Intelectin-2, 369
 Intercellular adhesion molecule (ICAM)
 ICAM-1, 466f, 477
 ICAM-2, 466f
 Interferon- γ (IFN- γ), 499, 618
 Interleukins. *See specific IIs*
 International Union of Biochemistry and Molecular Biology (IUBMB), 95
 Intravenous immunoglobulin (IVIg), 560
 Invasin, 457
 IQ-GPA, 712t, 714
 ISOGlyP, 122, 713t
 Isothermal titration calorimetry (ITC), glycan-binding protein studies, 392–393, 393f, 519
 ITAM, 463, 477, 480
 ITC. *See* Isothermal titration calorimetry
 ITI, 210–211
 ITI, 439
 ITIM, 463–464, 477, 480–481, 483, 485–486, 488
 ITP. *See* Immune thrombocytopenia
 I-type lectin. *See also* Siglec
 history of study, 489
 non-Siglecs, 476–478
 overview, 475
 IUBMB. *See* International Union of Biochemistry and Molecular Biology
 IVIg. *See* Intravenous immunoglobulin
- J**
- Jacalin, 428
 JAG1, 156
 JAG2, 156
 Japan Consortium for Glycobiology and Glycotechnology Database (JCGGDB), 709
 JCGGDB. *See* Japan Consortium for Glycobiology and Glycotechnology Database
 Jelly-roll fold, 432, 439–440
 JGT, 238
 Junk glycans, 86
- K**
- KCF. *See* KEGG Chemical Function
 KCP2, 108
 Kdn, 58, 191
 Kdo. *See* 2-keto-3-deoxyoctonic acid
 Kdp, CMP sugar for glycosylation, 60
 KEGG Chemical Function (KCF), 708
 KEGG. *See* Kyoto Encyclopedia of Genes and Genomes
 Keratan sulfate (KS)
 binding proteins, 518
 cancer changes, 638
 C-type lectin domains, 471
 degradation defects, 591–592
 history of study, 217
 structure, 11, 37f, 167, 224f
 synthesis, 225–226
 types, 223
 Keratanase, 678t
 Keratanase II, 678t
 Keratocan, 221
 3-keto-6-deoxyglucose, 61
 2-keto-3-deoxyoctonic acid (Kdo), 198, 201, 269, 288
 Ketose, definition, 3
 Keyhole limpet hemocyanin (KLH), 647–648
kfoE, 760
 KIAA1199 (CEMIP), 208
 Kifunensine, 110, 743f
Kingella kingae, 246
Klebsiella pneumoniae, 427, 780
 KLH. *See* Keyhole limpet hemocyanin
Kluyveromyces lactis, 658

- Krabbe disease, 587t, 593
 KS. *See* Keratan sulfate
 Kyoto Encyclopedia of Genes and Genomes (KEGG), 95
- L**
- L1, 625
 LacdiNAc. *See* Poly-*N*-acetylglucosamine
 LacNAc. *See* N-acetylglucosamine
Lactobacillus helveticus, 40f
Lactobacillus plantarum, 235
 Lactose synthase. *See* β 1-4 galactosyltransferase
 LAD-II, 612
Laetiporus sulphureus, 425
 LAM. *See* Lipoarabinomannan
 Laminaran, 332
 Laminin, 161, 182
 Laminin G domain, 382
 Landsteiner, Karl, 3f, 168
 Langerin, 462
 LAR, 360, 414, 415f
 LARGE, 99, 183
 LARGE1, 162, 606f, 607
 LARGE2, 162
 Laser-induced fluorescence (LIF), 695
 Lassa virus, 767
 Layilin, 456
 LCA, 646, 654, 655f, 658
 L1-CAM, 198
 LcH, 652
 LDL. *See* Low-density lipoprotein
 LDN. *See* Poly-*N*-acetylglucosamine
 LEC-1, 344
 LEC-6, 344
 Lectin. *See also* Glycan-binding proteins; *specific lectins*
 carbohydrate-recognition domain organization, 379–380
 classification, 375–376
 discovery, 368–369, 376–377
 glycan ligands, 383–385, 648f, 649f
 glycan recognition. *See* Glycan recognition
 glycan-recognizing probe application assays for glycosyltransferases and glycosidases, 659
 cell-surface glycoconjugate characterization, 656–657
 common examples, 646–647
 glycan identification, 652–654
 glycosylation mutant generation, 658
 glycosyltransferase gene cloning, 658–659
 historical perspective, 645–646
 purification of glycans and glycoproteins, 654–656
 recombinant lectins, 652
 history of study, 376–377
 identification by function and structure similarity, 383
 insects, 363–364
 nucleocytoplasmic lectins, 247–248
 protein folding, 406–407
 structural families, 380–383
 Lectin microarray, 657
 Lectin nucleotide phosphohydrolase (LNP), 543
 Leg. *See* Legionaminic acid
 Legionaminic acid (Leg), 198, 201f
Legionella pneumophila, 200, 237
Leishmania, 143, 150, 575–577, 576f
Leishmania amazonensis, 513
Leishmania donovani, 427, 570t
Leishmania major, 498, 570t, 576
Leishmania mexicana, 570t, 577
 Leloir, Luis, 3f
Lens culinaris, 646
 LERP, 363
 Leukemia inhibitory factor (LIF), 452
 Lewis blood group antigens. *See also specific antigens*
 Lewis antigen, 172–173
 synthesis, 172–173
 LFA-1, 477
 LFNG. *See* Lunatic fringe
 LGMDR21, 159
 LH. *See* Luteinizing hormone
 LH3. *See* Lysyl hydrolase 3
 Licensing, glycosylated therapeutics, 774
 LIF. *See* Laser-induced fluorescence; Leukemia inhibitory factor
 Lignin, 799
 LIMP-2, 452
 Link module, 209f, 211, 211f
 LINUCS, 708
 Lipid II, 283
 Lipid A, 287–289, 546, 558
 Lipid raft, 135, 150–151, 468, 481, 539, 589, 637–638, 639f
 Lipoarabinomannan (LAM), 85
 Lipoglycan, 301
 Lipomannan (LM), 286
 Lipooligosaccharide (LOS), 558–559
 Lipopeptidophosphoglycan (LPPG), 574, 577, 578f
 Lipophosphoglycan (LPG), 143, 501, 575–576
 Lipopolysaccharide (LPS), 39, 200, 212, 280
 assembly and export, 289–290, 289f
 function, 288, 289f
 glycan modulation of innate immunity, 546
 glycoengineering, 760
 immune signaling activation, 559
 structure, 286–288, 287f
 virulence factor, 558–560
 Lipoteichoic acid (LTA), 280–281, 284–286
Listeria monocytogenes, 809
 Liquid chromatography, 692f, 693, 695
 glycans, 676
 mass spectrometry coupling, 682
Lithobates catesbeianus, 494
 LM. *See* Lipomannan
 LMAN1, 437
 LNnT. *See* N-neotetraose
 LNP. *See* Lectin nucleotide phosphohydrolase
 Localized surface plasmon resonance (LSPR), 786–788
 LON-2, 344
 LOS. *See* Lipooligosaccharide
 Low-density lipoprotein (LDL), 616–617
 LOX-1, 462
 LPG. *See* Lipophosphoglycan
 L-PHA, 646, 647f, 653, 658
 LPPG. *See* Lipopeptidophosphoglycan
 LPS. *See* Lipopolysaccharide
 LptA, 290
 LptC, 290
 LptD, 290
 LRP1, 453
 LRP2, 453
 L-selectin (CD62L), 182, 198t, 199, 467–468, 470–471, 616–617, 619, 636, 642
 LSL, 425
 LSPR. *See* Localized surface plasmon resonance
 LT-1, 179
 LTA. *See* Lipoteichoic acid
 L-type lectin
 common features, 432–433
 history of study, 431–432
 jelly-roll fold, 432, 439–440
 pentraxin, 439
 plants
 distribution and localization, 433–434
 functions, 436
 structure, 434–436
 protein quality control and sorting
 calnexin, 436–437
 calreticulin, 436–437
 ERGIC-53, 437–438
 ERGL, 437–438
 VIP36, 437–438
 VIPL, 437–438
 rotavirus, 439
 Lumican, 221t, 638
 Lunatic fringe (LFNG), 158
 Lung cancer, 642
 Luteinizing hormone (LH), sulfated GalNAc, 176–177
 LY6K, 151
 LYK1, 542
 LYK9, 542
 LYR4, 542
 Lysosome
 genetic defects in glycan degradation overview, 584–586, 586t
 treatment, 596–597
 glycoprotein degradation defects, 586, 588–589, 586t, 587t
 inhibition of glycan degradation, 595–596
 overview of enzymes, 583–584
 Lysyl hydrolase 3 (LH3), 163
 LYVE-1, 208, 211, 213, 638

M

- Maackia amurensis*, 436
 Mac-1, 477
 MacLeod, Colin, 556
 Macrophage galactose-binding lectin (MGL), 462, 622
 Mad cow disease, 153
 MadCAM-1, 470
 MAG, 483
 MAG. *See* Myelin-associated glycoprotein
 MAGIC, 712t
 Magnetic nanoparticle, 788–789, 789f
 Magnetic resonance imaging (MRI), 788–789, 789f, 793–794
 MAGT1, 108, 605
 MAGT1-CDG, 605
 MAH, 463
 Major capsid protein (MCP), 245–246
 Malaria, 152–153, 190, 196, 514, 569
 Mallard reaction, 617
 MAN1A1. *See* α -mannosidase IA
 MAN1B. *See* α -mannosidase IA2
 MAN1B1. *See* α -mannosidase I
 MAN1B1-CDG, 605
 MAN1C1. *See* α -mannosidase IC
 MAN2A1, 110, 372, 761
Man2a2, 669
 MAN2A2, 110, 372
 MANEA, 110
 Manic fringe (MFNG), 158
 ManNAc. *See* N-acetylmannosamine
 ManNAz. *See* N-azidoacetylmannosamine
 Mannose, glycosylation precursor metabolism, 58
 Mannose-binding lectin (MBL), 96, 461
 Mannose-binding protein-A, 456–457, 458f
 Mannose-1-phosphate, 58
 Mannose-6-phosphate, 58
 Mannose-6-phosphate receptor (M6PR), 89, 112. *See also* P-type lectin
 CD-MPR, 447–449, 448f, 451, 656
 CI-MPR, 447–451, 448f
 common features, 447–448
 evolutionary origins, 451
 homology domain, 446, 453
 mutation studies, 449
 recognition marker discovery, 444
 enzymatic generation, 445–446, 445f
 nonlysosomal proteins, 452
 subcellular trafficking, 449–451, 450f
 M6PR. *See* Mannose-6-phosphate receptor
 Mannose-P-serine, 77
 Mannose receptor, 426–427
 Mannostatin A, 743f
 Mannosyltransferase-1 (MT-1), 147
 Mannosyltransferase-2 (MT-2), 147
 Mannosyltransferase-3 (MT-3), 147
 MAPK. *See* Mitogen-activated protein kinase
 Marfan syndrome, 614
 Maroteaux–Lamy disease, 587t
mas1, 351
 MASCOT, 714
 MASP-1, 461, 462
 MASP-2, 461, 462
 Mass spectrometry (MS)
 congenital disorder of glycosylation diagnosis, 601
 data analysis software tools, 711, 712–714
 derivatization of glycans, 695
 fragmentation of N- and O-linked glycans, 697, 698f
 gas chromatography/mass spectrometry monosaccharide composition analysis, 681
 O-GalNAc glycans, 120
 glycan-binding protein studies, 396
 glycomics, 691, 693–694
 glycosphingolipids, 133
 glycosylation analysis, 14
 high-throughput analysis, 809
 ionization techniques
 ESI, 682, 684, 696
 MALDI, 682, 684, 696
 linkage analysis, 682, 684
 O-GlcNAc lability, 254
 profiling of N- and O-linked glycans, 696–697
 sialic acid, 194
 tandem mass spectrometry of N-glycopeptides 701f
 Mast cell, 229, 486–487, 500, 626
 Matriglycan, 162, 271
 MatrixDB, 710t
 MBL. *See* Mannose-binding lectin
MBL2, 96, 461–462
 MCAW, 97
 McCarty, Maclyn, 556
 MCFD2, 437
 MCP. *See* Major capsid protein
 MD. *See* Molecular dynamics
 MD2, 288
 MDL-1, 462
 MEB. *See* Muscle–eye–brain disease
 MECA-79, 470, 651
 Megalin, 453
 Melanoma, 139, 483, 637, 642, 780
 Meningococcus Group B, 273
 Metachromatic leukodystrophy, 587t
 Methanochondroitin, 98, 300–301
Methanococcoides burtoni, 98
Methanococcus maripaludis, 304–305
Methanococcus voltae, 98, 304–305
Methanopyrus, 298
Methanosarcina, 300
Methanosarcina barkeri, 98
Methanospaera stadtmanae, 98
Methanospirillum hungatei, 301, 305
Methanothermobacter formicifer, 298
 4-methylumbelliferone, 214
 Meyer, Karl, 205
 MFNG. *See* Manic fringe
 MGAT1, 110–112, 114, 371, 667, 761, 765, 767. *See also* GlcNAcT-I, GnT-1
Mgat1, 350, 352t, 354, 355f
 MGAT2, 110, 373, 605, 761, 763. *See also* GlcNAcT-II, GnT-II
 MGAT3, 111, 632, 633f, 641, 653, 764. *See also* GlcNAcT-III, GnT-III
 MGAT4, 632, 633f. *See also* GlcNAcT-IV, GnT-IV
 MGAT4A, 110
 MGAT4B, 110
 MGAT4C, 110–111
 MGAT5, 110, 114, 167, 500, 632, 633f, 641. *See also* GlcNAcT-V, GnT-V
 MGAT5B, 110, 162
 MGDG. *See* Monogalactosyldiacylglycerol
 MGEA5, 256
 MGL. *See* Macrophage galactose-binding lectin
 MGUS. *See* Monoclonal gammopathy of unknown significance
 Microarray. *See* Glycan microarray
Microbacterium nematophilum, 342
 Microbiome. *See* Gut microbiota
 Miglitol (Glyset), 773f
 Miglustat, 743f, 773f
 Milk. *See* Human milk oligosaccharides
 Miller Fisher syndrome, 625
 Mimecan, 221t
Mimivirus, 428
 MINCLE (CLEC4E), 462, 464
 Mincle, 384
 miR-30d, 101
 MIRAGE, 710t, 711, 808
 Mitochondria, protein glycosylation, 241–242
 Mitogen-activated protein kinase (MAPK), 460
 MK-8719, 744f, 745
 MM. *See* Molecular mechanics
 MMP-9, 640
 MND. *See* Motor neuron disease
 Modeccin, 658
 MOGS. *See* α -glucosidase I
 Molecular dynamics (MD), 413–415
 Molecular mechanics (MM), 413, 415
 Molecular mimicry, 84–85, 273
 Monoclonal antibodies to glycan antigens
 antigen examples, 650f, 651f
 historical perspective, 645–646
 generation, 647–651
 glycan identification, 652–654
 purification of glycans and glycoproteins, 654–656
 cell-surface glycoconjugate characterization, 656–657
 glycosylation mutant generation, 658
 glycosyltransferase gene cloning, 658
 assays for glycosyltransferases and glycosidases, 659
 Monoclonal gammopathy of unknown significance (MGUS), 625
 Monogalactosyldiacylglycerol (MGDG), 242, 332, 333f
 Monosaccharide

- amino groups, 30
 anomeric center. *See* Anomeric center
 common units of glycoconjugates, 8–9
 composition analysis, 681
 cyclic versus acyclic form, 23, 26
 definition, 3
 diversity in nature, 812–813
 glycosylated protein composition, 696f
 hydroxyl group. *See* Hydroxyl group, monosaccharide
 intracellular sources for glycosylation
 activation and interconversion
 fucose, 58
 galactose, 58–59
 glucose, 56–57
 glucuronic acid, 57
 glycogen, 56
 iduronic acid, 57
 mannose, 58
 N-acetylgalactosamine, 60
 N-acetylglucosamine, 59–60
 sialic acid, 60
 xylose, 57–58
 bacteria and plants, 60–61
 salvage, 55
 linkages, 7–8
 salvage, 595
 stereoisomerism, 22–23
 structure, 22–23
 Morquio syndrome, 587t
 MotifFinder, 97
 Motor neuron disease (MND), 261
 Mouse models
 CRISPR/Cas9, 370f
 environmentally driven phenotypes, 373
 muscular dystrophy, 371
 mutations
 cell type–specific mutations, 372
 glycosylation pathway, 371
 specific glycan extensions or modifications, 371–372
 strain differences and genetic modifiers, 373
 Moxetumomab pasudotox, 482
 MPDU1, 106
 MPI, 602t
 MPI-CDG, 602t, 604, 613, 618
 MPS. *See* Mucopolysaccharidosis
 MraY, 298
 MRC1, 177
 MRI. *See* Magnetic resonance imaging
 MRP-1, 242
 MS. *See* Mass spectrometry
 MsbA, 289
 MSD. *See* Multiple sulfatase deficiency
 MSFragger-Glyco, 712t, 714
 MT-1. *See* Mannosyltransferase-1
 MT-2. *See* Mannosyltransferase-2
 MT-3. *See* Mannosyltransferase-3
 MTG, 363–364
 MtgA, 97
 MTX, 428
 Mucin. *See also* O-GalNAc glycan
 cancer expression, 633–634, 634f
 definition, 10
 discovery, 117
 diseases, 119
 genes, 119
 isolation, purification, and analysis, 120–121
 MUC1, 119, 642
 MUC2, 119
 MUC16, 642
 O-GalNAc glycan cores and antigens, 118f
 salivary gland, 552
 sialoglycans, 195
 structure, 118f
 Mucopolipidosis I. *See* Sialidosis
 Mucopolipidosis II. *See* I-cell disease
 Mucopolipidosis III. *See* Pseudo-Hurler polydystrophy
 Mucopolysaccharidosis (MPS), 586, 587t, 597
 Multi-lectin affinity chromatography, 656
 Multiple, myeloma, 138, 642
 Multiple sulfatase deficiency (MSD), 587t, 591
 Multivesicular body (MVB), 594
 Murein. *See* Peptidoglycan
 MurG, 97, 298
 MurNAc. *See* N-acetylmuramic acid
 Muscle–eye–brain disease (MEB), 607
 Mussels. *See* R–type lectin, invertebrates
 MVB. *See* Multivesicular body
Mycobacterium tuberculosis, 379, 427, 464
Mycoplasma, 280
Mycoplasma pneumoniae, 167, 621
 MyD88, 546, 559
 Myelin, 136
 Myelin-associated glycoprotein (MAG; Siglec-4), 137, 182, 197, 476, 479, 482–483
 Myeloglycan, 137
 Myerhof, Otto, 3f
 MytiLec, 425
 Myzozyme, 597
- N**
- N-acetylgalactosamine (GalNAc)
 glycosylation precursor metabolism, 60
 nucleocytoplasmic glycoproteins, 234
 structure, 10
 N-acetylgalactosamine-1-P, 60
 N-acetylgalactosaminidase, 120
 N-acetylgalactosaminyltransferase, 134
 N-acetylglucosamine (GlcNAc), 14f, 59–60, 68, 252, 283, 776, 781
 N-acetylglucosamine-1-P, 59
 N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase), 47, 71, 77, 446f
 N-acetylglucosamine-6-P, 59
 N-acetylglucosaminyltransferase (GlcNAcT), 147, 658
 GlcNAcT-I, 49–50, 340–341, 350
 GlcNAcT-II, 50
 N-acetylhexosamine, 55
 N-acetylglucosamine (LacNAc), 11, 68
 cancer changes, 632
 evolutionary variations, 269
 glycosylation extensions, 166
 polymers on blood groups, 167–168
 N-acetylmannosamine (ManNAc), 59–60, 776
 N-acetylmannosamine-6-P, 59–60
 N-acetylmuramic acid (MurNAc), 78, 283–284, 298
 N-acetylneuraminic acid (Neu5Ac), 625, 776
 CMP sugar for glycosylation, 60
 deacetylation, 77
 glycosphingolipid synthesis, 134
 metabolism, 192f
 Siglec biology, 488
 structure, 24f
 N-acetylneuraminic acid-9-P, 60
 NADPH oxidase, 540
 Naglazyme, 597
 NAGPA, 112
 NAGPA, 446
 Nanotechnology
 cellulose nanocrystals, 799–800
 glyconanomaterials
 carbon-based materials
 carbon nanotube, 790–791, 791f
 fullerene, 790
 graphene, 791–792
 diagnostics and therapy, 793
 glycodendrimers, 792
 overview, 785–786, 787f
 polysaccharide-based materials, 786, 792–793
 prospects, 794
 types and applications, 786
 inorganic nanoparticles
 gold nanoparticles, 786–788, 788f
 magnetic nanoparticles, 788–789, 789f
 quantum dot, 789
 NANS, 611
 N3 antigen, 726
 National Center for Biotechnology Information (NCBI), 94
Natronococcus, 300
 Natural killer cell, 462, 464, 467, 471, 486–488
 Natural killer T cell, 137
 Natwicz disease, 587t
 N-azidoacetylmannosamine (ManNAz), 676
 N-azidoacetylsialic acid (SiaNAz), 676
 N-butyldeoxyojirimycin, 596, 746
 NCAM. *See* Neural cell adhesion molecule
 NCBI. *See* National Center for Biotechnology Information
 NDST1, 226
 NDST4, 226
Necator americanus, 571
Neisseria gonorrhoeae, 558–559

- Neisseria meningitidis*, 41, 97, 291, 294–295, 481, 497, 556–557, 780
- Nematodes. *See Caenorhabditis elegans*
- Nephropathy, 207, 372, 611, 624
- Nephrotic syndrome, 624
- Nerve growth factor receptor, 136
- NetOGlyc, 122
- NEU1, 193–194
- NEU2, 193
- NEU3, 193
- NEU4, 193
- Neu5Ac. *See* N-acetylneuraminic acid
- Neu5Gc. *See* N-glycolylneuraminic acid
- NeuD, 192
- Neural cell adhesion molecule (NCAM), 71, 83–85, 90, 142, 180–182, 190, 243, 477, 553, 557, 625
- Neuraminatase pyruvate lyase (NPL), 611
- Neuraminidase, 193, 506–507, 564, 588, 749f, 772. *See also* Sialidase
- Neuroblastoma, 139, 642
- Neurocan, 209, 221
- Neurofibrillary tangle, 261
- Neurofibromatosis type 1, 363
- Neuromuscular junction (NMJ), 357, 360
- Neuropilin-2, 125, 190
- Newcastle virus, 465
- NFR1, 543
- NFR5, 543
- NF- κ B. *See* Nuclear factor- κ B
- NG2, 222–223
- NGi-1, 740f
- NGLY1, 243, 247, 534, 545, 602t, 605
- NGLY1-CDG, 602t
- N-glycan
 - branching, 34–35, 34f, 111f
 - cancer, branching and fucosylation, 632, 633f
 - chemoenzymatic synthesis, 733, 736f
 - classes and nomenclature, 104, 104f
 - congenital disorders of glycosylation. *See* Congenital disorders of glycosylation
 - deuterostomes, 368
 - discovery, 103–104
 - evolutionary variation, 266–269
 - functions, 113–114
 - glycoengineering
 - bacteria, 760–761
 - insects, 763–764
 - mammalian cells, 764–766
 - plants, 762–763
 - yeast, 761–762
 - glycoforms, 113
 - insect assembly and diversity, 350–351, 354–355
 - isolation, purification, and analysis, 105
 - lysosomal degradation, 585f, 588–589
 - lysosomal hydrolase phosphorylated N-glycans, 112
 - mapping of glycosylation sites, 699
 - nematodes, 337–338, 340–341
 - N-glycosylation site prediction in eukaryotes, 104–105
 - nucleocytoplasmic glycoproteins, 242–243
 - plants, 323, 330–331
 - protein folding, 530–531
 - recycling, 594–595
 - removal from proteins, 534–535, 535f
 - structure, 10
 - synthesis
 - dolichol-linked precursor synthesis, 106–107
 - transfer to nascent protein, 106, 108
 - early processing steps, 108–110, 109f
 - late processing steps, 110–111, 109f
 - maturation, 109f, 111–112
 - overview, 104–105, 166
 - transferases and transporters, 113
- N-glycolylneuraminic acid (Neu5Gc), 60, 93, 134, 190–191, 199, 270, 488–489, 625, 635f, 636
- NgR1, 483
- NgR2, 483
- NGT, 246
- NHEJ. *See* Nonhomologous end joining
- Nicotiana benthamiana*, 762–763
- Niemann–Pick disease, 586, 746
- Nipah virus, 465
- NIST Glycan Reference, 713t
- NKG2D, 605
- NleB, 237
- NLS. *See* Nuclear localization signal
- NMJ. *See* Neuromuscular junction
- NMR. *See* Nuclear magnetic resonance
- N-neotetraose (LNnT), 514
- Nobel laureates, glycobiology, 3
- Nod factor, 543–544, 543f
- Nodal, 152
- NodC, 544
- Nodes of Ranvier, 136
- NodZ*, 544
- Nogo receptor, 483
- Nonaka myopathy. *See* Hereditary inclusion body myopathy type II
- Nonhomologous end joining (NHEJ), 759
- Nonreducing end glycan, 6
- oligosaccharides, 30–31, 30f
- Nonulosonic acid (NuLO). *See also* Sialic acid
- discovery and classification, 186
- diversity, 812
- nomenclature, 202
- overview, 185–186
- prokaryotes, 200–201
- structures, 187f
- synthase, 270
- Notch, 83, 94, 156, 158
- development role, 550–551
- Drosophila melanogaster*, 157–158, 160, 357–358, 358f
- knockout mouse, 371
- Ofut1 substrate, 536
- signaling, 159f
- NOTCH1, 157, 160
- NPL. *See* Neuraminatase pyruvate lyase
- NPL, 194, 611
- Nuclear factor- κ B (NF- κ B), 260, 460, 464, 558, 641
- Nuclear localization signal (NLS), 248
- Nuclear magnetic resonance (NMR)
 - data analysis software tools, 714
 - glycan mobility, 623
 - glycan three-dimensional structure determination, 687–688, 687f, 807–808
 - glycan-binding protein studies
 - binding studies, 396
 - structure studies
 - bound ligand geometry and ligand interaction surfaces, 408–411
 - chemical-shift mapping, 408, 409f
 - principles, 407–408
 - glycosphingolipids, 133
 - glycosylation analysis, 14
 - HSQC, 408, 685–687, 686f
 - linkage analysis, 685–687, 686f
 - O-GalNAc glycans, 120
 - Skp1, 238, 239f
- Nucleocytoplasmic glycosylation
 - assembly intermediates, 246
 - complex glycosylation
 - glycogenin, 240–241
 - Skp1, 238–240
 - enzymes, 247–248
 - evolutionary variation, 271–272
 - examples, 236t–237t
 - glycosyltransferases in nucleus, 244
 - monoglycosylation
 - eukaryotes, 234
 - prokaryotes, 234–235
 - toxins in bacteria, 237–238
 - N-glycans, 242–243
 - O-glycans, 244
 - overview, 233–234
 - prospects for study, 248–249
 - secretion, 245–246
 - topography of glycosylation, 235f
- Nucleotide sugars. *See specific nucleotide sugars*
- NuLO. *See* Nonulosonic acid
- NUS1, 612
- ## O
- O-acetylation
 - glycans, 77
 - ulcerative colitis and cancer, 619
- O-antigen polysaccharide (O-PS), 287–290
- Oesphagostomum dentatum*, 346
- OFT. *See* O-fucosyltransferase
- O-fucose, 235
- O-fucose glycan
 - epidermal growth factor repeats, 157–158
 - thrombospondin type 1 repeats, 160–161, 161f
- O-fucosyltransferase (OFT), 806
- Ofut1, 94, 535–536
- OGA. *See* O-GlcNAcase
- O-GalNAc glycan. *See also* Mucin

- core structures, 119–120
 functions, 125–126
 history of study, 117, 119
 isolation, purification, and analysis, 120–121
 synthesis
 complex glycans, 124–125
 core synthesis, 122f, 123–124, 123f
 defects, 607–608
 overview, 121–122, 121t
 polypeptide-N-acetylgalactosaminyltransferases, 121–123
 O-GalNAc transferases, 69
 O-GlcNAcase (OGA), 46, 253–257, 260, 262–263, 640, 744–745
 O-GlcNAc glycan
 cycling control
 dynamics, 257
 OGA, 256–257
 OGT, 255–256, 255f
 overview, 254–255
 databases, 259
 epidermal growth factor repeats, 160, 252
 examples, 254t
 functions
 epigenetics and transcription regulation, 260
 overview, 253f, 254, 259
 protein translation, stability, and turnover, 260
 survival signaling, 262–263
 history of study, 251–252
 knockout studies, 258
 O-phosphate interplay, 259
 overview, 13, 251, 252f
 pathology
 cancer, 262, 640–641
 diabetes and elevated levels, 261–262
 neurodegenerative diseases, 260–261
 processing enzyme inhibitors, 744–745, 750
 prospects for study, 263, 811–812
 protein distribution, 258–259
 O-GlcNAc transferase (OGT), 70, 74, 254–256, 255f, 258, 260, 262–263, 340–341, 357, 371, 640, 671, 744, 750
 O-glucose glycan, epidermal growth factor repeats, 158–160
 O-glycan. *See also* Epidermal growth factor repeats; O-GalNAc glycan
 branching, 34–35
 cancer and truncation, 634, 634f
 cell culture synthesis mutants, 671
 collagen, 163
 congenital disorders of glycosylation. *See* Congenital disorders of glycosylation
 degradation defects, 589
 endoplasmic reticulum quality control reactions, 535–536
 evolutionary variation, 270–271
 glycoengineering
 bacteria, 761
 insects, 764
 mammalian cells, 766–767
 plants, 763
 yeast, 762
 insect assembly and diversity, 355–358
 kidney disease changes, 624
 mapping of glycosylation sites, 699
 nematodes, 337–338, 341–342
 nucleocytoplasmic glycoproteins, 244
 plants, 329–330
 structure, 10
 O-glycanase, 120
 OGT. *See* O-GlcNAc transferase
 Oligosaccharide
 branching and diversity, 34–35
 definition, 5, 21, 33
 milk. *See* Human milk oligosaccharides
 Oligosaccharyltransferase (OST), 69, 106–108, 266–267, 532f, 544, 760
 O-mannose, 77
 O-mannose glycan, 161–162, 162f, 606f, 607
Onchocerca volvulus, 346, 571
 O-Pair, 712t, 714
 Open-chain form, monosaccharide, 3, 5
 OpeRATOR, 121
 OpgG, 292
 OpgH, 292
 OPGs. *See* Osmoregulated periplasmic glucans
 O-PS. *See* O-antigen polysaccharide
Oryza sativa, 424
 OS9, 110, 453, 534
 OSMi-1, 744f
 OSMi-4, 744f
 Osmoregulated periplasmic glucans (OPGs), 291–292
 OST, 604–605
 OST. *See* Oligosaccharyltransferase
 Ost3p, 106, 108
 Ost6p, 106, 108
 OSTA, 108
 OSTB, 108
 Osteoarthritis, 214, 622, 778–779
 Osteochondrodysplasia, 609
 Osteoclast, 479–480
 Osteoglycin, 221
 Ovalbumin, 103
 O-xylosyltransferase, 70
- P**
- P0, 182, 478, 625
 p53, 260, 641
 p62, 243
 p67, 260
 p97, 534
 p180, 243
 PA14 domain, 382
 PAH. *See* Pulmonary arterial hypertension
 Palmer, John, 205
 PAM. *See* Phosphatidylinositol mannoside
 PAMPs. *See* Pathogen-associated molecular patterns
 Paper chromatography, 680
 PAPS. *See* Phosphoadenosine-5'-phosphosulfate
 PAPSS1, 469
 Parasitic infection. *See also specific diseases and parasites*
 epidemiology of diseases, 569, 570t
 glycan-binding proteins, 573t
 glycan receptors, 513t
 parasites
 Entamoeba, 577, 578f
 Leishmania, 575–577
 overview, 569–571
 Plasmodia, 571–573
 Schistosoma, 578–580
 trypanosomes, 573–575
Parelaphostrongylus tenuis, 346
 Parkinson's disease, 260–261, 593
 Paucimannose, 110, 320, 330, 340, 346, 350, 394, 762–763
 Paroxysmal cold hemoglobinuria, 621
 Paroxysmal nocturnal hemoglobinuria (PNH), 152, 620–621
 Parvovirus B19, 174
Pasteurella multocida, 97
 Pasteur, Louis, 308
 Patentability, glycosylated therapeutics, 774
 Pathogen-associated molecular patterns (PAMPs), 84, 279, 284, 288, 427, 461, 464, 540–541, 546, 558
 PaTox, 561
 PBCV-1, 245–246
 P blood group antigens, synthesis, 173–174, 174f, 621
 PC1. *See* Polycystin-1
 PCLP, 470
 PCT. *See* Pharmacological chaperone therapy
 PD-1, 468, 643
 PDB. *See* Protein Data Bank
 PDB-Care, 712t
 PdhC, 235
 PDI. *See* Protein disulfide isomerase
 PD-L1, 643
 PDX-1, 260–261
 Peanut agglutinin (PNA), 434–435, 435f, 658, 789
 PECAM-1, 198, 477
 Pectin
 cell wall, 328
 structure, 36, 322f, 327–328
 synthesis, 329
Penacus japonicus, 500
 Penetrin, 573
 Penicillin, 284
Penium margaritaceum, 331
 Pentose, definition, 8
 Pentraxin, 439
 PEP. *See* Phosphoenolpyruvate
 Peptide-N-glycosidase (PNGase), 243, 534, 592
 PNGase A, 105, 678t, 680
 PNGase F, 105, 244, 252, 656, 677, 678t, 680, 694, 699

- Peptidoglycan
 cell wall assembly, 283–284
 structure, arrangement, and function, 280, 282–283, 282f
 synthesis therapeutic targeting, 284
- Periodic acid–Schiff reaction, 676
- Periodontitis, 561
- Perlecan, 219, 221, 223
- PET. *See* Positron emission tomography
- Peters-plus syndrome, 161
- Petromyzon marinus*, 650
- PFK1, 262, 641
- PGANT, 121, 357
- PGAP1, 152, 609
- PGAP2, 609
- PGAP3, 609
- PGAP6, 152
- PGIP. *See* Polygalacturonase-inhibiting protein
- PglB, 290–291, 760
- PglK, 291
- pGlyco, 712t, 714
- PGM1-CDG, 611
- PgtA, 240
- PH-20, 208
- PHAL. *See* Phytohemagglutinin L
- Pharmacological chaperone therapy (PCT), 596, 777–778
- Phaseolus vulgaris*, 646
- Phosphacan, 223
- Phosphatidic acid, 151
- Phosphatidylinositol mannoside (PAM), 286
- Phosphoadenosine-5'-phosphosulfate (PAPS), 45, 61, 77, 125, 225, 364
- Phosphoenolpyruvate (PEP), 191, 283
- Phosphoglucosyltransferase, 56
- Phosphoglucose isomerase, 56
- Phosphoglycosylation, 77
- Phospholipase C (PLC), 141–142
- Phospholipase D (PLD), 152
- Phosphomannomutase 2, 371
- Phosphorylation, glycans, 182–183
- Phospho-N-acetylglucosamine mutase, 59
- Photorhabdus asymbiotica*, 561
- PHYAL1, 208
- Phylogeny, cellular forms of life, 266–267, 267f
- Phytohemagglutinin, 376
- Phytohemagglutinin E, 436
- Phytohemagglutinin L (PHAL), 435
- Phytophthora sojae*, 540
- PI-88, 642
- PI3K, 638
- Pichia pastoris*, 761
- Pierisin, 420f, 426, 428
- PIGA, 151–152, 609, 620–621, 637
- PIGB, 152, 609
- PIGC, 609
- PIGF, 609
- PIGG, 609
- PIGH, 609
- PIGK, 609
- PIGL, 602t, 609
- PIGM, 609
- PIGN, 609
- PIGO, 609
- PIGP, 609
- PIGQ, 609
- PIGS, 609
- PIGT, 152, 609
- PIGV, 609
- PIGW, 609
- PIGY, 609
- PIG-Z, 150
- PILR α , 476–477
- PILR β , 476–477
- Pilus, 509f, 560, 560f, 788
- PirB, 483
- Pisum sativum* agglutinin (PSA), 658
- PKC. *See* Protein kinase C
- PKD1, 471
- Plants
 cell wall
 overview, 324–325
 primary glycans, 325–328
 secondary glycans, 328–329
 defenses, 541f
 glycan diversity, 320–321, 322f
 glycan signaling
 defense response, 540–542
 developmental signaling, 543–545
Rhizobium–legume symbiosis, 543
 glycoengineering
 N-glycans, 762–763
 O-glycans, 763
 overview, 762
 glycolipids, 332–333
 glycosylphosphatidylinositol anchors, 330
 glycosyltransferases, 320, 324
 L-type lectins
 distribution and localization, 433–434
 functions, 436
 structure, 434–436
 metabolic carbohydrates, 324
 mutant studies of glycan function, 321, 323–324
 N-glycans, 323f, 330–331, 331f
 nucleotide sugars, 320
 O-glycans, 329–330
 oligosaccharins, 542
 polysaccharide detection, 679
 R-type lectins, 419–425
 secondary metabolites, 333
 Viridiplantae clades, 319
- Plasma cell myeloma, 625
- Plasmapheresis, 560
- Plasmodium falciparum*, 98, 190, 196, 513–514, 570t, 571–573, 571f, 573t, 580
- Plasmodium malariae*, 570t
- Plasmodium ovale*, 570t
- Plasmodium vivax*, 570t
- Plastic, production, 799
- PLC. *See* Phospholipase C
- PLD. *See* Phospholipase D
- PLE. *See* Protein-losing enteropathy
- Plexin, 360
- pmHas, 214
- PMM2, 602t, 604
- PMM2-CDG, 602t, 604
- PNA. *See* Peanut agglutinin
- PNAG. *See* Poly-N-acetylglucosamine
- Pneumocystis carinii*, 427, 461
- PNGase. *See* Peptide-N-glycosidase
- PNH. *See* Paroxysmal nocturnal hemoglobinuria
- Podoplanin (Aggrus), 464
- POFUT1, 47, 70–71, 94, 158–161, 340–341, 371, 535–536, 671
- POFUT1-CDG, 158
- POFUT2, 70–71, 160–161, 341–342, 536
- Pofut2*, 160
- POGLUT1, 47, 159–160, 671
- POGLUT1*, 159
- POGLUT2, 160
- POGLUT3, 160
- Polycomb, 357
- Polycystin-1 (PC1), 471
- Polygalacturonase-inhibiting protein (PGIP), 540
- Poly-N-acetylglucosamine (PNAG), 292–294, 562
- Poly-N-acetylglucosamine (LacdiNAc; LDN), 11, 355, 579
- Polyomavirus, 507
- Polysaccharide
 animal cell surfaces. *See*
 Glycosaminoglycan
 bacteria features, 39–42
 definition, 21, 33
 storage functions, 36
 structural functions, 35–36
- Polysaccharide A (PSA), 294
- Polysaccharide-based nanoparticle. *See* Nanotechnology
- Polysialic acid
 NCAM, 180–181, 190
 protein distribution, 190
 structure, 12, 189–190
- POMGNT1, 162, 606f, 607
- POMGNT2, 162, 606f, 607
- POMK, 162, 183, 607
- Pompe disease, 586, 596–597, 777
- POMT1, 161, 270, 602t, 606f, 607, 671, 762
- POMT2, 161, 270, 606f, 607, 671, 762
- Porcine reproductive and respiratory syndrome virus (PRRSV), 272
- Positron emission tomography (PET), 794
- PP1. *See* Protein phosphatase 1
- PP-13, 493
- PPL-13, 493
- PRC2, 260
- Precipitation, glycan-binding protein studies, 399, 656–657
- Prion, 142, 153, 243, 518t
- Prolectin (CLEC17A), 464
- Proliferin, 452
- Properdin, 161
- Prosaposin, 593
- Proteasome, 260, 529
- Protective group. *See* Chemical synthesis

- Protein C, 551
 Protein Data Bank (PDB), 404–405, 688, 715
 Protein disulfide isomerase (PDI), 534
 Protein folding. *See* Glycoprotein folding
 Protein kinase C (PKC), 213
 Protein-losing enteropathy (PLE), 618–619, 625, 778
 Protein O-fucosyltransferase I. *See* POFUT1, 158–161
 Protein phosphatase 1 (PP1), 259
 Protein Prospector, 714
 Protein S, 551
 Proteoglycan. *See also* Glycosaminoglycan; *specific proteoglycans*
 cell culture assembly mutants, 670–671
 composition, 218
 C-type lectin domains, 471
 detection, 677
 diversity, 218–220, 221t–222t
 history of study, 217–218
 insects, 359–360
 nematodes, 342–344
 structure, 219f
 processing and turnover, 230
 vertebrate forms and functions, 220–223
 Proteomics. *See* Glycoproteomics
 Proteophosphoglycan (PPG), 576–577
 PRRSV. *See* Porcine reproductive and respiratory syndrome virus
 PSA. *See* *Pisum sativum* agglutinin; Polysaccharide A
 Pse, 198
 P-selectin (CD62P), 182, 197, 466–468, 466f, 616, 619, 636, 642
 P-selectin glycoprotein ligand-1 (CD162; PSGL-1), 83, 126, 384–385, 466–469, 466f, 471, 616–617, 620
 Pseudo-Hurler polydystrophy, 447, 584
Pseudomonas aeruginosa, 200, 342, 439, 722, 723f
 Pseudomurein, 298, 300f
 Pseudopeptidoglycan. *See* Pseudomurein
 PSGL-1. *See* P-selectin glycoprotein ligand-1
 PST. *See* ST8SIA4
 PTS domain, 119
 PTX1, 439
 PTX2, 439
 PTX3, 439
 PTX4, 439
 P-type lectin. *See also* Mannose-6-phosphate receptor
 CI-MPR ligands, 451–452
 common features, 447–448
 evolutionary origins, 451
 history of study, 443–447
 mutation studies, 449
 subcellular trafficking, 449–451
 PUGNAc, 744f, 745
 Pull-down assay, glycan-binding protein studies, 392
 Pulmonary arterial hypertension (PAH), 627–628
 Pulmonary embolism, 627
 PVL, 407
 PXYLP1, 183
 Pyruvate dehydrogenase, 235
Pythium ultimum, 240
- ## Q
- QD. *See* Quantum dot
 Quantum dot (QD), 789
 Quantum mechanics simulation, 413–414
- ## R
- RA. *See* Rheumatoid arthritis
 Radical fringe (RFNG), 158
 Raf-1, 464
 RAGE. *See* Receptor for advanced glycation end products
 RANK, 483
 RANTES. *See* CCL5
 Ras, 363
 Rb, 260, 641
 RCA. *See* *Ricinus communis* agglutinin
 RCA-I, 420–421, 423
 RCA-II. *See* Ricin
 Receptor for advanced glycation end products (RAGE), 618
 RECK, 152
 Reducing end
 glycans, 5
 oligosaccharides, 30–31, 30f
 Reg3 α , 472
 Relative reactivity value (RRV), 726–727
 Relenza, 199, 564, 750, 772–773, 774f
 Reovirus, 507
 Reperfusion injury, selectin role, 616
 RFNG. *See* Radical fringe
RFT1, 106
 RHAMM (CD168), 211, 213, 638
 Rhamnogalacturonan, 322f, 327
 Rhamnogalacturonan I, 322f
 Rhamnogalacturonan II, 322f, 327–328
 Rhamsan, 40, 40f
 Rheumatoid arthritis (RA), 622–623
Rhinella arenarum, 494
Rhizobium, 506
Rhizobium–legume symbiosis, 543
rib-1, 344
rib-2, 344
 Ribitol-5-P, 162
 Ribophorin I, 106
 Ribophorin II, 106
 Ricin
 β -trefoil fold, 423, 424f
 carbohydrate-binding specificity, 421–422, 658
 cellular uptake, 422f
 history of study, 419–420
 sequence, 423
 structure, 420–421, 421f
 toxicity, 422–423
Ricinus communis, 419–420
Ricinus communis agglutinin (RCA), 656, 787
 Ring form, monosaccharide, 3, 5
 RINGS, 713, 713t
 RIP-I, 422
 RIP-II, 422, 422f
 RIPK, 237
 Rivipansel (GMI-1070), 468, 619, 781
 RNA interference, 672, 792
 RNA polymerase II, 238, 252, 259–260
 RNA-N-glycosidase, 658
 RNA-N-glycosylase, 421–423
 RNase 2, 156
 Robbins, Phil, 308
 Roseman, Saul, 68
 Rossman fold, 72
 Rotavirus, 507
 Rothman, James, 3f
 Rpt2, 260
 RRV. *See* Relative reactivity value
 Rt, 357
 R-type lectin. *See also* Ricin
 Archaea, 428–429
 bacteria, 428
 domain structures, 420f, 424f
 fungi, 425
 history of study, 419–420
 invertebrates, 425–426
 plant, 423–425
 prospects for study, 429
 protists, 425
 Q-X-W motif, 423
 UDP-GalNAc:polypeptide α -N-acetyl-galactosaminyltransferase, 426, 427f
 vertebrate mannose receptors, 426–427
rumi, 159
 Ruthenium red, 6
 RXYLT1, 162
RXYLT1, 607
- ## S
- S100A12, 525
 SAA. *See* Serum amyloid A
 Saba, 196
 SABP1, 580
Saccharomyces cerevisiae
 glycoengineering, 762
 glycosylphosphatidylinositol anchor synthesis, 144–148, 147t–148t
 S-adenosyl methionine (AdoMet), 45
 Salla disease, 193
Salmonella enterica, O-polysaccharide, 39
Salmonella Typhi, 190, 197, 556, 561
 SAM. *See* Self-assembled monolayer
Sambucus nigra, 195, 423, 436
Sambucus nigra agglutinin (SNA), 243, 424, 652, 676
 SAMPs. *See* Self-associated molecular patterns
 SAMT-1, 342
 Sandhoff disease, 587t, 596
 Sanfilippo syndrome, 587t
 SAP. *See* Saposin
 SAP. *See* Serum amyloid P

- Saposin (SAP), 592–593
 deficiency, 587t
 SAP-A, 593
 SAP-B, 593
 SAP-C, 593
 SAP-D, 593
- SARS-CoV-2, 465, 507, 518, 563, 623, 806
- Saturation transfer difference nuclear magnetic resonance (STD NMR), 409–411, 410f, 414
- SBA. *See* Soybean agglutinin
- SCD. *See* Sickle cell disease
- SCF, 238
- Scheie syndrome, 587t, 589, 596
- Schekman, Randy, 3f
- Schiff base, formation, 28
- Schindler disease, 586t
- Schistosoma haematobium*, 571t, 578, 578f
- Schistosoma japonicum*, 571t, 578, 578f
- Schistosoma mansoni*, 464, 497, 571t, 578–579, 578f, 579f
- Scrapie, 153
- Sda blood group antigen, 178f, 637
- Sdc, 360
- SDS-PAGE, 253, 288–289, 676, 679, 695
- Sea urchin, egg glycans and fertilization, 366, 368
- SEC. *See* SECRET AGENT
- SEC23B, 613
- SecA2, 246
- SECRET AGENT (SEC), 258
- SecY2, 246
- Selectin. *See also specific selectins*
 cancer expression of ligands, 636–637, 636f
 cell adhesion, 378
- Selenoprotein C, 525
- Self-assembled monolayer (SAM), 793
- Self-associated molecular patterns (SAMPs), 84–85, 197, 270, 276, 489, 546, 551
- Semantic Web, 709, 710t
- Semaphorin, 360
- Seminolipid, 130f
- Sendai virus, 507
- Serglycin, 222–223
- Serrate, 156
- Serum amyloid A (SAA), 525
- Serum amyloid P (SAP), 439
- SeviL, 424f, 425
- sfl*, 359
- SGLT-1, 55
- SGLT-2, 55
- Sgp200, 470
- Shewanella oneidensis*, 291
- Shiga toxin, 513
- Shigella dysenteriae*, 513
- Shigella flexneri*, O-antigens, 40
- SHP-1, 464, 480, 485
- SHP-2, 480, 485
- SIAE. *See* Sialate 9-O-acetyltransferase
- Sialate 9-O-acetyltransferase (SIAE), 77, 194
- Sialate O-acetyltransferase (SOAT), 77
- Sialic acid. *See also specific sialic acids*
 biophysical roles, 195
 cancer studies
 expression, 199, 635–636
 O-acetylation, 619
 CMP sugars for glycosylation, 60, 62–63, 113, 125, 191
 control of glycosylation precursor pools, 64
 developmental functions, 198
 discovery and classification, 186
 evolutionary distribution, 199–200
 evolutionary variation, 269–270
 glycan
 diversity, 186–189
 linkage diversity, 188f
 modifications, 191–193
 sialic acid release, 193
 synthesis, 191
 termination, 35
 glycosylation, 54
 glycosylation precursor metabolism, 60
 lectins, 195, 197–198
 O-acetylation in disease, 619
 polymers. *See* Polysialic acid
 protein examples, 196t
 recognition by pathogens and toxins, 196–197
 recycling and degradation, 193–194
 sialome complexity, 189f
 structures, 24, 187f
 synthesis defects, 611
 therapeutic targeting, 199
 tools for study, 194–195
- Sialidase, 120, 624. *See also* Neuraminidase
 bacteria, 623–624
 deficiency, 586t, 587t
 enzymatic release of sialic acid, 193–195
 glycan analysis, 678t
 inhibitors, 749
 lysosomal, 588
 mitochondria, 248
trans-sialidase, 191, 439, 573–574, 749
 viruses, 199, 506–507, 564, 750
- Sialidosis, 587t
- Sialin (SLC17A5), 193
- Sialoadhesin (CD169; Siglec-1), 476, 478–481
- Sialuria, 64
- Sialyl Lewis a, 635–636, 642, 652
- Sialyl Lewis x (CD15s), 550–551, 616, 635–636, 641–642, 647, 652, 731f, 741, 747f, 782f, 789
- Sialyl-6-sulfo Lewis x, 637
- Sialyltransferase, 350–351. *See also* *SiaT*
- SiaNAz. *See* N-azidoacetylsialic acid
- SiaT*, 200
- Sickle cell disease (SCD), 468, 619–620
- Siglec. *See also specific Siglecs*
 CD33-related Siglecs
 genomic organization, expression patterns and functions
 CD33, 484f, 485, 485f
 overview, 484
 Siglec-5, 486
 Siglec-6, 486
 Siglec-7, 486–487
 Siglec-8, 487
 Siglec-9, 486–487
 Siglec-10, 488
 Siglec-11, 488
 Siglec-14, 486
 Siglec-16, 488
 Siglec-E, 486–487
 Siglec-F, 487
 Siglec-G, 488
 nonsialylated ligands, 489
 cell type-restricted expression, 479–480
 classification, 489
 domain structures, 477f
 expression patterns and functions
 CD22, 481–482
 myelin-associated glycoprotein, 482–483
 sialoadhesin, 480–481
 Siglec-15, 483
 history of study, 489
 human-specific changes in biology, 488–489
 masking and unmasking, 478–479
 tyrosine-based signaling motifs, 480
 V-set sialic acid-binding domain, 478, 479f
- Siglec-1. *See* Sialoadhesin
- Siglec-2, 275, 643
- Siglec-4. *See* Myelin-associated glycoprotein
- Siglec-5, 484, 486, 489
- Siglec-6, 480, 486
- Siglec-7, 479–480, 486–487, 489
- Siglec-8, 478, 487
- Siglec-9, 211, 486–487
- Siglec-10, 385, 488
- Siglec-11, 480, 488, 489
- Siglec-12, 484, 489
- Siglec-14, 480, 484, 485–486, 489
- Siglec-15, 476, 479–480, 483–485
- Siglec-16, 480, 484–485, 488–489
- Siglec-17, 489
- Siglec-E, 484, 486–487
- Siglec-F, 484, 487, 627
- Siglec-G, 481–482, 484, 488
- Siglec-H, 480, 484
- Siglec-like binding region, 652
- SIGN-R1. *See* CD209a
- SimGlycan, 712t
- SimpleCell, 699
- Single-particle analysis (SPA), cryo-electron microscopy, 411
- SIRP α , 488
- Site-1-protease (S1P), 446
- Size exclusion chromatography, 680
- Skp1, 238–240, 239f
- SLC2A, 54
- SLC5A, 54
- SLC5B4, 63
- SLC17A5. *See* SLC17A5
- SLC26A2, 609
- SLC35A1, 611, 622

- SLC35A2, 605
 SLC35A2-CDG, 605
 SLC35C1-CDG, 612
 SLC35D1, 609
 SLC39A8, 613
 SLE. *See* Systemic lupus erythematosus
 Sleeping sickness, 569
sll, 364
 SLRP. *See* Small leucine-rich proteoglycan
 Sly disease, 587t
slytherin, 369
 Small leucine-rich proteoglycan (SLRP), 220, 230
 Smp3, 150
 SNA. *See* *Sambucus nigra* agglutinin
 Snail, 642
 SNAIL, 641
 SNFG. *See* Symbol Nomenclature for Glycans
 SN2 reaction, 74, 75f, 76–77, 722, 730
 SOAT. *See* Sialate O-acetyltransferase
 Sodium borohydride, alditol formation, 28f
 Sodium/potassium-ATPase, 243
 Sorbitol, 779
 Sortilin, 453
 Soybean agglutinin (SBA), 433f, 658
 S1P. *See* Site-1-protease
 Sp1, 260
 SPA. *See* Single-particle analysis
 SP-A, 461
 SPACR, 211
 SPACRCAN, 211
 SPAM1, 208, 210
 SP-D, 461
 Speciation, glycan role, 813
 SPG26, 610
 Sphingosine, 130
 SpNanA, 193
 SpNanB, 193
 SpNanC, 193
Spodoptera frugiperda, 350, 763
 Sponge, carbohydrate–carbohydrate interactions, 83
 SPPL3, 113
 SPR. *See* Surface plasmon resonance
 SPRINT-Gly, 712t
 Spy, 234
 SPY, 258
 SQV-1, 58, 342–343
 SQV-4, 342–343
 SQV-7, 342
 SRC, 213
 Src, 464
 SRD5A3, 612
 SRD5A3, 602t
 SRD5A3-CDG, 602t
 SRRP, 246
 SRT. *See* Substrate reduction therapy
 SSEA-1, 550, 647, 658. *See also* LeX; CD15
 SSEA-3, 550, 641
 SSEA-4, 550
 SSGlcNAc, 744f
 SSGlcNH₂, 744f
 ST3GAL1, 124, 178–179, 622, 763
St3gal1, 178
 ST3GAL3, 178, 198, 610
 ST3GAL4, 178, 622
St3gal5, 178
 ST3GAL5, 138, 198, 610
 ST3GAL6, 178
St3gal6, 179
 ST6Gal-I, 47, 50, 90
 ST6GAL1, 179, 275, 415–416, 416f, 641, 732
St6gal1, 179, 765
 ST6GAL1, 635, 641, 762
 ST6GAL2, 179
St6gal2, 179
 ST6GALNAC1, 123–124, 179–180, 634
 ST6GALNAC2, 179
 ST6GALNAC3, 179
 ST6GALNAC4, 124, 179
 ST6GALNAC5, 179
 ST6GALNAC6, 179
 ST8SIA1 (GD3 synthase), 180–183
 ST8SIA2 (STX), 180–181, 198
 ST8SIA3, 181
 ST8SIA4 (PST), 125, 180–181
 ST8SIA6, 180
 Starch
 linkages, 5
 torsion angle, 36f
 STAT5, 260
 StcE, 121
 STD NMR. *See* Saturation transfer difference nuclear magnetic resonance
 Stereoisomerism, monosaccharides, 22–23
Streptococcus epidermidis, 562
Streptococcus mutans, 652
Streptococcus pneumoniae, 193, 292, 459, 514, 557f, 623
Streptococcus pyogenes, 561
Strongylocentrotus purpuratus, 367f
Strongyloides stercoralis, 571t
 Streptomycin, 60–61
 Stillmark, Hermann, 419
 Structural analysis, glycans. *See also* Mass spectrometry
 derivatization of released glycans for analysis, 695
 detection
 glycolipid, 677–678
 glycoprotein, 677
 glycosylphosphatidylinositol anchor, 679
 plant and bacterial polysaccharides, 679
 proteoglycan, 677
 techniques, 676–677
 drawing of glycan structures, 707–708
 linkage analysis
 mass spectrometry, 682, 684
 nuclear magnetic resonance, 685–687, 686f
 position, 681–682, 683f
 modified glycans, 697
 monosaccharide composition analysis, 681
 nuclear magnetic resonance three-dimensional structure, 687–688, 687f
 overview, 675–676
 prospects, 697–698
 release from glycoconjugates, 680, 694–695
 separation techniques, 680
 STT3, 106, 108, 290, 302, 604–605
 STT3A, 605
 STT3A-CDG, 605
 STT3B, 605
 STT3B-CDG, 605
 Stt3p, 106
 STX. *See* ST8SIA2
 Substrate reduction therapy (SRT), 596, 777
 SugarBind, 710t
 SugarPy, 712t
 SugarQb, 712t
 Sulfated glycosaminoglycan-binding proteins. *See also* Glycan-binding proteins
 antithrombin–heparin interactions, 521–523
 binding study techniques, 518–519
 CCL5–chondroitin sulfate interactions, 524–525, 524f
 classification, 375–376
 discovery, 377
 FGF–heparin interactions, 523–524, 524f
 glycan recognition. *See* Glycan recognition
 heparin oligosaccharide conformation, 519–520
 identification by function and structure similarity, 383
 metal cofactors, 525
 overview, 517–518
 pH dependence, 525
 prospects for study, 526
 specificity of binding, 520–521
 Sulfatide, 136
 Sulfation, glycans, 182
Sulfolobus acidocaldarius, 304
 Sulfotransferase. *See also* specific sulfotransferases
 O-GalNAc synthesis, 124
 overview, 77
 Support vector machine (SVM), 715
 Surface plasmon resonance (SPR), glycan-binding protein studies, 393–395, 394f, 519
 Sushi domain, 465
 SV2, 222
 SV40, 537, 667
 SVM. *See* Support vector machine
 Swainsonine, 596, 743, 743f
 Sweet-II, 712t, 715
 SYK, 464
 Symbol Nomenclature for Glycans (SNFG), 8, 40f, 707–708
 SynCAM 1, 190
 Syndecan, 344, 359
 Syndecan-1, 373, 640

Synexin, 499
Systemic lupus erythematosus (SLE), 480, 482, 486, 624–625

T

tACE, 151–152
TACE, 470
Tachylectin-2, 407f
Taeniarhynchus saginatus, 571t
Taenia solium, 571t
TALEN, 368, 370f, 664, 758, 767
Taliglucerase alfa, 777
Tamiflu, 199, 564, 750, 772–773, 774f
Tamm–Horsfall protein, 178, 510
Tandem mass tag (TMT), 701
Tau, 243, 261, 625–626
Tax, 641
Tay–Sachs disease, 130, 138, 587t, 596
T-cell receptor (TCR), 499–500
TCGA. *See* The Cancer Genome Atlas
TCR. *See* T-cell receptor
TDP-glucose, 61
TEA-32, 573
Teichoic acid, 546
Tenascin-C, 471
Tenascin-R, 471
Teladorsagia circumcincta, 580
Telencephalin, 182
TEM. *See* Transmission electron microscopy
Tenascin-C, 471
Tenascin-R, 471
TET proteins, 260
TEX101, 151
Thermodynamics, glycan binding, 389–390, 389f
Thermoplasma acidophilum, 301
Thiamet-G, 744f
Thickveins, 360
Thin-layer chromatography (TLC)
 gangliosides, 131
 glycans, 676
 glycolipids, 677–678
 glycosphingolipids, 133
5-thio-*N*-acetylglucosamine, 741
Thomsen–Friedenreich antigen, 119
Thrombin, 619
Thrombomodulin, 223
Thrombospondin type 1 repeats (TSRs)
 C-mannosylation, 163
 modifications, 161f
 nematodes, 337
 O-fucose glycans, 160–161
Thy-1, 6f, 141–143, 669
Thyroglobulin, 452
Thyroid hormone, forms, 552
Thyroid-stimulating hormone (TSH),
 sulfated GalNAc, 176–177, 177f
Tissue-nonspecific alkaline phosphatase
 (TNALP), 609
TLC. *See* Thin-layer chromatography
TLR. *See* Toll-like receptor
TMEM165, 613
TMEM2, 208

TMT. *See* Tandem mass tag
TMTC1, 270, 671
TMTC2, 671
TMTC3, 671
TMTC4, 270
Tn polyagglutinability syndrome, 621–622
TNALP. *See* Tissue-nonspecific alkaline
 phosphatase
TNFR1, 237
TNF- α . *See* Tumor necrosis factor- α
TOCSY, 685–687
Toll-like receptor (TLR), 84, 279, 480,
 545–546
 TLR-2, 212–213, 286, 464, 558, 572
 TLR-4, 212–213, 288, 464, 558–559
Topiramate, 773f
Torpedo, 141
Torsion angle
 cellulose versus starch, 36
 glycosidic bond, 31–32, 31f
ToxA, 237
Toxin A, 513
Toxocara canis, 346
Toxocara cati, 346
Toxoplasma carinii, 570t
Toxoplasma gondii, 234, 238, 258, 426, 493,
 513, 570t, 580
TPST2, 469
TRA-1-60, 550
TRA-1-81, 550
TRADD, 237
Transferrin, 601, 605
Transforming growth factor- β , 452
Transfusion reaction, 620, 781
Transmission electron microscopy (TEM),
 788, 802f
Transplantation, rejection, 781–782
Trans-sialidase (TS), 439
Trehalose 6-phosphate phosphatase, 100
TREX1, 544–545
Trichinella spiralis, 346, 571t
Trichiuris trichiura, 571t
Trichomonas vaginalis, 497, 501, 570t
Trichuris suis, 346
Triflic acid, 725, 727
Triflic anhydride, 722
Trimeresurus albolabris, 472
TrkA, 137
trNOE, 408–409
Trypanosoma brucei, 238, 570t, 748
 glycosylphosphatidylinositol synthesis,
 144–146, 151
 variant surface glycoprotein, 141–143,
 152, 573–574
Trypanosoma cruzi, 481, 513, 570t,
 574–575, 575f, 580
TS. *See* *Trans-sialidase*
TSG-6, 210–211, 211f, 409f, 439
TSH. *See* Thyroid-stimulating hormone
TSP-1, 440
TSRs. *See* Thrombospondin type 1 repeats
T-synthase, 464, 469, 621
Tumor necrosis factor- α (TNF- α), 467, 469,
 553, 616, 618

Tunicamycin, 88, 106, 740f, 742
TUSC1, 108
Tw, 357

U

UDP-apiose, 57, 61
UDP-2-deoxyglucose, 741
UDP-Gal, 175
UDP-galactose, 58–59, 62–63, 63t, 74, 88
UDP-GalNAc, 122
UDP-GalNAc:polypeptide α -*N*-acetyl-
 galactosaminyltransferase, 426
UDP-GlcNAc, 77, 106, 262, 272, 283, 618
UDP-glucose, 106
UDP-glucose ceramide glucosyltransferase
 (Ugcg), 138
UDP-glucose glycoprotein
 glucosyltransferase (UGGT), 47,
 71, 74, 437, 530–533, 530f, 532f,
 536
UDP-glucose pyrophosphorylase, 57
UDP-glucuronic acid, 61, 63
UDP-MurNAc, 283
UDP-*N*-acetylglucosamine, 62–63
UDP-*N*-acetylhexosamine
 pyrophosphorylase, 64
UDP-xylose, 57f, 61, 63, 224
Ugcg. *See* UDP-glucose ceramide
 glucosyltransferase
UGGT. *See* UDP-glucose glycoprotein
 glucosyltransferase
Ulcerative colitis, 619
UNC-52, 344
Undecaprenyl-P, 65
Unfolded protein response (UPR), 64
UniCarb-DB, 712t, 713
UniLectin, 407f, 710t
UniProt, 95
Upd, 360
UPR. *See* Unfolded protein response
Urinary tract infection (UTI), 623
Uromodulin, 510
Uronic acid, definition, 8
UTI. *See* Urinary tract infection

V

Vaccine, glycan components
 cancer vaccine, 780–781
 microbial vaccine, 780
VAR2CSA, 572–573
Variable lymphocyte receptor (VLR), 650
Variant surface glycoprotein (VSG),
 141–143, 152, 573–574, 574f
Varicella zoster virus (VSV), 452
Vascular endothelial growth factor (VEGF),
 640
VAV2, 213
VEGF. *See* Vascular endothelial growth
 factor
VEGFR2, 499
Velaglucerase, 777
Venglustat, 746

- Versican, 209, 221
v-fps, 641
Vibrio cholerae, 179, 428, 439, 511, 512f, 512t, 618, 624
Vibrio vulnificus, 559
Vicia faba, 436
Vicia villosa agglutinin (VVA), 656
VIP, 363
VIP36, 433, 437–438, 533
VIPL, 437–438
Viridiplantae. *See* Algae; Plants
Viruses
 glycan-binding receptors, 379
 glycome, 97
 hemagglutinins, 507t
 host cell entry
 herpes simplex virus, 562, 564–565
 human immunodeficiency virus, 562, 565–566
 influenza, 563–564
 overview, 562–563
 host glycosylation machinery, 272
 lectins, 506–508, 507t
 R-type lectins, 428–429
VLR. *See* Variable lymphocyte receptor
Voglibose (Glustat), 773f
von Willebrand factor (vWF), 172, 178
VP54, 245
Vpu, 537
VRG4, 63
VSG. *See* Variant surface glycoprotein
v-src, 641
VSV. *See* Varicella zoster virus
VVA. *See* *Vicia villosa* agglutinin
vWF. *See* von Willebrand factor
- W**
- WAK1, 542
Waldenström's macroglobulinemia, 621, 625
Walker–Warburg syndrome (WWS), 602t, 607
Wall teichoic acid (WTA), 280, 284–286, 290, 295
Warburg effect, 262
Welan, 40
- West Nile virus, 465
WFA. *See* *Wisteria floribunda* agglutinin
Wg, 360
WGA. *See* Wheat germ agglutinin
Wheat germ agglutinin (WGA), 235, 248, 658
Whooping cough, 561
Wisteria floribunda agglutinin (WFA), 823
WND motif, 456
WNT, 640
Woese, Carl, 297
WTA. *See* Wall teichoic acid
Wuchereria bancrofti, 571t
WURCS, 708, 715
WWS. *See* Walker–Warburg syndrome
Wzx, 290, 294
Wzy, 294
Wzz, 290
- X**
- Xanthomonas campestris*, 294
Xenopus, 544
Xenopus laevis
 advantages as model system, 368
 galectins, 494
 lectin discovery, 368–369
Xenotransplantation, 175, 179, 781
XL35, 368–369
XPS. *See* X-ray photoelectron spectroscopy
X-ray crystallography
 galectins, 493
 glycan-binding protein structure studies
 antithrombin–heparin interactions, 522–523, 522f
 carbohydrate-binding site interactions, 405–406, 406f
 databases, 405
 fibroblast growth factor–heparin interactions, 523–524, 524f
 folding in lectins, 406–407
 principles, 405
X-ray photoelectron spectroscopy (XPS), 788
XTP3-B, 453
XXYL1, 160
- Xylitol, 779
Xyloglucan, 326, 544
Xylogalacturonan, 322f, 327
Xylose
 glycans, 99, 112, 160, 162, 224
 glycosylation precursor metabolism, 57–58, 57f
 salvage, 55
Xyloside, 746–748
Xyloside α -1-3 xylosyltransferase, 160
Xylosyltransferase, 70, 99–100, 112, 160, 353t, 358, 670t, 757t, 760. *See also specific enzymes*
XYLT1, 224, 608
XYLT2, 224, 608
Xyn10A, 428
- Y**
- Yarrowia lipolytica*, 756t
Yeast. *See also* Fungi; *specific yeasts*
 glycoengineering
 N-glycans, 761–762
 O-glycans, 762
 overview, 761
 glycosylphosphatidylinositol anchor
 synthesis, 144–148, 147t–148t
Yersinia, 237
Yersinia enterocolitica, 291
Yersinia pestis, 342
Yersinia pseudotuberculosis, 342, 457
Yos9p, 534
YY1, 260
- Z**
- Zanamivir. *See* Relenza
Zebrafish
 advantages as model system, 369
 galectins, 494
 glycosylation-related phenotypes, 369–371
Zika virus, 509, 518t
ZIP8, 613
Zymosan, 460